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ABSTRACT 
 
IMPACT OF GESTATIONAL EXPOSURE TO 
2,3,7,8-TETRACHLORODIBENZO-p-DIOXIN 
ON T LYMPHOCYTE DEVELOPMENT 
by 
Lori S. Ahrenhoerster 
The University of Wisconsin-Milwaukee, 2014 
Under the Supervision of Professor Michael D. Laiosa 
 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a ubiquitous environmental 
contaminant and the best characterized agonist of the arylhydrocarbon receptor 
(AHR), a transcription factor crucial to the detoxification of numerous xenobiotics. 
Studies in animals show that TCDD is immunosuppressive in adult exposures, 
and epidemiological studies have found an association between TCDD exposure 
and hematologic cancers. Additionally, developmental exposure to TCDD has 
been shown to increase the likelihood of autoimmunity and to impair immune 
response to later-life infections. The cells of the immune system are all 
descended from multipotent hematopoietic stem cells (HSCs) that originate in the 
fetus. This multipotency, defined as the ability to develop into several different 
cell types, suggests that any impact on HSCs potentially affects all cells arising 
from the original HSCs throughout the life course. During particularly sensitive 
timepoints such as puberty and pregnancy, alterations initiated by early life 
exposures can be triggered to cause immune disorder by shifts in hormone 
  iii 
levels, stress, or other endogenous means. The effect that developmental 
exposures have on later life immune disease is not completely understood, but 
epidemiological statistics suggest that the rise in immunological disease is 
associated with a changing environment, whether due to chemical, microbial, or 
as-yet-unknown contributing factors. We investigated the effects of 
developmental AHR activation on later-life immune outcomes and used a mouse 
model to examine T lymphocyte development following gestational exposure to 
environmentally relevant levels of TCDD. We found that developmental exposure 
to TCDD significantly decreased the lymphocyte differentiation potential of HSCs, 
and that this effect occurs through the fetal AHR. We also found that AHR 
signaling is involved in crosstalk with the Notch1 gene—a gene which has been 
linked to over half of the cases of T cell acute lymphoblastic leukemia. These 
studies support the role of developmental exposure to environmental 
contaminants in the development of immune disease and may lead to multiple 
public health focused interventions such as development of treatments, 
implementation of preventative measures, and changes in environmental policy. 
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CHAPTER 1 
 
 
 
GENERAL INTRODUCTION 
 
 
 
 
  
  
2 
I. Introduction  
 
Disease development is multi-faceted, but increasingly it has become 
apparent that early life exposures—including those while still in utero—can have 
profound effects on later life disease progression. This concept, the 
Developmental Origins of Health and Disease (DOHaD), provides a potential 
explanation for the recent increase in hematological based diseases such as 
cancer, immune suppression, allergy, and autoimmunity. Common intrauterine 
exposures are nutritional or hormonal, but numerous other exposures are also 
known to impact the fetus’s development. For example, stress during pregnancy 
has not only been linked to poor birth outcomes, which can lead to a host of 
health issues, but it can also result in later-life disease in offspring. Additionally, 
health can be affected by other factors such as parity or gender ratio in multiple 
births. It is now known that chemical and microbial environmental exposures 
during pregnancy can impact birth outcomes and fetal health. Many 
environmental contaminants exert their toxicity in adults through the 
arylhydrocarbon receptor (AHR). Given the increase in incidence of 
hematological based diseases, we wanted to determine whether developmental 
exposure to AHR agonists such as 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) 
affects hematopoietic stem cells, the process of hematopoiesis, and later life 
hematological processes. 
This research focuses on developmental exposure to the ubiquitous 
environmental contaminant TCDD, but many additional intrauterine effects can 
also impact the development of disease. While the studies described involve 
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responses in the immune system following hematopoietic stem cell (HSC) 
exposures, stem cells of other lineages might be similarly altered and tissues 
formed from those stem cells might also contribute to disease later in life. This 
effect is particularly important when applied to vulnerable populations who may 
be starting life already at a disadvantage in terms of nutrition or genetics. 
Understanding the contribution of developmental influences to later life health is 
a Public Health priority. Not only is there a need for disease cures, but also 
means of disease prevention. Furthermore, better understanding of the 
connection between contaminants and diseases could inform future 
environmental regulation policies.  
 
II. Human Development and the Life Course 
In 1991, a connection was made between insufficient gestational growth 
due to inadequate maternal nutrition and later-life development of coronary heart 
disease (Barker, 2007, 1991). Since that discovery over two decades ago by the 
physician David Barker, what is now known as the Barker hypothesis or DOHaD 
has been applied to additional health effects including type 2 diabetes and 
cardiovascular disease (Power et al., 2013), neurodevelopment (Monk et al., 
2013), reproductive function (Dupont et al., 2012), and immunological disease 
(Dietert, 2011, 2009; Faulk and Dolinoy, 2011). While Dr. Barker originally made 
his connections based on nutrition during pregnancy, other environmental 
exposures, including medications and toxic chemicals, can alter physiology 
during gestational development, particularly at sensitive timepoints (Fig. 1), 
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resulting in later life disease (Barouki et al., 2007; Susiarjo et al., 2013). Many 
immune diseases do not manifest until adulthood, making connection to 
developmental exposures complicated. However, associations are being 
discovered, and a recent study has connected prenatal exposure to several 
persistent environmental contaminants with an increased chance of developing 
asthma twenty years later—the longest range study of its type done to date (S. 
Hansen et al., 2013).  
 
Figure 1. Sensitive timepoints exist in the life course. Experiences and exposures 
occurring during gestational development may impact health at later sensitive times of 
development, including childhood, puberty, during the childbearing years, or later. 
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A. Epidemiology of Immune Disease 
The incidence of immune disorders such as asthma (Centers for Disease 
Control and Prevention, 2011), allergies (Jackson, KD et al., 2013), cancer, 
diabetes (Centers for Disease Control and Prevention, 2013), and autoimmune 
diseases is rising worldwide (Bach, 2002; Cooper et al., 2009), and while the 
impact on adult health is substantial, children are particularly susceptible. 
Leukemia, the most common childhood cancer, is responsible for 30% of 
childhood cancer (Belson et al., 2007; U.S. Cancer Statistics Working Group, 
2013), and it is estimated that over 25% of children in developed countries have 
an immune disorder (Dietert and Zelikoff, 2010). While cure rates for childhood 
leukemia are on the rise (Belson et al., 2007) and many advances have been 
made in adult leukemia cure rates (Mathisen et al., 2013), most other immune 
disease treatments are minimally effective at best. Known inherited factors and 
single nucleotide polymorphisms have been linked to development of some 
immune diseases including autoimmunity (Perl, 2012) and cancer (Du et al., 
2013; Han et al., 2013; Mosor et al., 2013; Perez-Andreu et al., 2013), and many 
immune disorders tend to run in families or are common in identical twins 
(Cooper et al., 2009; Rogler, 2011). However, the rise in rates is far too rapid to 
be attributable to genetic susceptibility alone (Barouki et al., 2012; Schmidt, 
2011), which suggests an interaction between genes and the broader 
environment.  
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Environmental influence can refer to chemicals or infectious agents in the 
air, water, and other surroundings (Belson et al., 2007; Fazekas de St Groth, 
2012; Selmi et al., 2012; Selmi, Carlo et al., 2011), or it can more specifically 
refer to exposures in utero and be compounded by maternal factors such as diet, 
tobacco use, or stress (Prescott and Noakes, 2007; Walker and Ho, 2012).  
Given that the increase in immune disease rates correlates with the 
increase in industrialization of developing countries, a further examination of the 
gene-environment connection is warranted. Though the United States, through 
Public Health programs such as the Clean Air Act and Clean Water Act, has 
decreased emissions of environmental contaminants such as benzene, volatile 
organic compounds and particulates, many others persistent in the water and 
soil. Additionally, developing countries do not have as stringent environmental 
protections, and in addition to chemical contaminants, a new environmental risk 
has emerged. The United States and other developed countries send electronic 
waste, such as discarded computers, to developing nations in Asia and Africa 
where they are informally recycled by incineration, raising soil and air levels of 
dioxins, flame retardants and other toxic substances to dangerous levels (Tue et 
al., 2013).  
A particular strength of our research model is that we use a relatively low 
dose of TCDD (3µg/kg) in our developmental exposures to mimic environmental 
levels. Many others who work with TCDD and immunity administer doses 
between 3 and 10 times higher (10-30 µg/kg) and work with adult animals 
(Benson and Shepherd, 2011; Casado et al., 2011; Dere et al., 2011; Funatake 
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et al., 2008; Gasiewicz et al., 1983; Laiosa et al., 2003). We administer 
developmental doses through the mother, and given that less than 0.5% of 
TCDD crosses the mouse placenta (Van den Berg et al., 1994; Weber and 
Birnbaum, 1985), the fetuses receive even lower amounts than the dam. The 
maximum total TCDD exposure is approximately 30 ng/kg (3µg/kg x 2 doses x 
0.5% = 0.03µg/kg or 30 ng/kg). As a point of human comparison, total infant 
exposure to TCDD is estimated to be approximately 5.5 ng/kg in the infant’s first 
six months (Gogal and Holladay, 2008). However, in more polluted areas, such 
as rapidly-developing areas in Asia, the infant would have an even higher 
exposure level.  
 
B. Developmental Biology and Stem Cells 
Developmental exposures cause heightened concern about environmental 
contaminants because an organism’s time in utero is particularly sensitive to 
environmental insult due to the development of stem cells. Stem cells are 
undifferentiated cells responsible for replenishing themselves, and differentiating 
along explicit cell lineages. Because all tissues in the body are descendants of 
early stem cells, any effect on early stem cells is carried with the organism 
throughout its lifetime. Each organ system is formed during a particular 
timeframe (Fig. 2), during which that system is most vulnerable to outside 
influences. As an example, gestational week eight is when the immune system 
begins to develop, though initiated from stem cells formed even earlier in 
gestation.  
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Figure 2. Each organ system has specific sensitive developmental windows. The 
first 1000 days of life post-conception are particularly vulnerable timepoints in 
development, as the foundation of all organ systems is being formed. The various 
systems are illustrated above, along with the most sensitive times in their development 
(Altshuler, Berg et al. 2003). 
 
 
C. Immune System Development 
 
Hematopoiesis, the process by which immature precursor cells or HSCs 
develop into mature blood and immune cells, is initiated in the yolk sac in both 
mice and in humans (Fig. 3) (Orkin and Zon, 2008; Samokhvalov et al., 2007). In 
mice, the anatomical location and timing of hematopoiesis proceeds in such a 
way that the HSCs migrate, and the site of hematopoiesis moves to the aorta-
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gonads-mesonephros (gestational day (GD) 8-9), then the fetal liver and spleen 
(GD11), and finally to the bone marrow, which remains the site of hematopoiesis 
throughout adulthood (Dzierzak and Medvinsky, 1995; Orkin and Zon, 2008; 
Robin, C et al., 2003). Though lengths of gestation differ, human hematopoietic 
development proceeds in the same sequence as in mice. All HSCs, regardless of 
location, are capable of self-renewal and differentiation in both the fetus and 
adult organisms (Orkin and Zon, 2008).  
 
Figure 3. HSC location migrates throughout gestation. Timeline showing location of 
hematopoiesis, including dosing regimen, for mice used in this research. For HSC 
harvest, mice were administered vehicle or 3 µg/kg TCDD on GD 0.5 and 7.5. For adult 
experiments, treatments continued for GD14.5 and PPD2.5. 
 
 All mammalian blood and immune cells develop from hematopoietic stem 
cells and originate in the fetal liver or the bone marrow of an adult. At the top of 
the hierarchy (Fig. 4) are a very rare population of multipotent long-term (LT) 
HSCs, which are self-renewing and capable of differentiation into any cells of the 
blood and immune system. Identifiable by the presence of several surface 
markers, including CD150, along with the absence of CD48 and CD244 in the 
mouse, LT HSCs comprise approximately 0.01% of whole bone marrow (Oguro 
et al., 2013) and 0.10% of the fetal liver (Kim et al., 2006). Multipotent HSCs 
must maintain a balance between differentiation into the many mature blood and 
GD0.5 GD7.5 GD14.5 
HSC in yolk 
sac 
HSC in aorta-gonads-
mesonephros (AGM) 
HSC in liver 
and spleen 
GESTATION)
Day of vehicle or TCDD gavage 
HSC move to postnatal anatomical 
site in bone marrow 
birth Child/ adult 
Day of HSC harvest 
PPD2.5 
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immune cells, and quiescence (resting in the Go cell cycle) as self-renewing, 
undifferentiated HSCs.  
 A larger but less specific subset of HSCs are identifiable by the absence 
of cell surface markers for lineage-committed cells (Table 1) along with the 
presence of surface markers Sca-1 and cKit (Li et al., 1995; Oguro et al., 2013; 
Spangrude, G J et al., 1988). This heterogeneous population of short-term (ST) 
HSCs, known as LSKs (Lin-Sca1+cKit+), are easily identifiable and commonly 
employed in HSC research. LSKs are the HSC population isolated and used in 
the experiments described here.  
 In a healthy system, each HSC will form two daughter cells—for 
replacement and differentiation. In response to micro-environmental signals in 
the stem cell niche, a proportion of HSCs begin differentiation along myeloid or 
 
Figure 4. All blood cells descend from hematopoietic stem cells (HSCs). HSCs 
gradually lose potency (differentiation potential) and renewal potential, becoming more 
specialized. The first split is between myeloid or lymphoid lineages. 
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lymphoid pathways (Fig. 4), and become committed to progressively more 
specific lineage fate options (Luc et al., 2008). Myeloid committed precursors can 
become thrombocytes (platelet-forming cells), erythrocytes (red blood cell 
forming), mast cells, basophils, neutrophils, eosinophils, macrophages, or 
dendritic cells. The lymphoid committed precursors can become dendritic cells or 
can take one of two lymphocytic paths. Some of the undifferentiated lymphocyte 
progenitors travel to the thymus, where they receive signals from a 
transmembrane protein known as Notch1, resulting in maturation to T 
lymphocytes (T cells). The other progenitors remain in the bone marrow, do not 
receive Notch1 signals, and mature into B lymphocytes (B cells) (Deftos et al., 
2000; Zúñiga-Pflücker, 2004). 
Table 1. Cell surface markers included in LSK panel 
Abbreviation Function Cell type it identifies 
CD32 T cell co-receptor T lymphocytes 
LY-76/Ter-1192 Lymphocyte antigen 76 Erythroid cells 
CD45R/B2202 
Protein tyrosine 
phosphatase, receptor 
type, C 
B lymphocytes 
CD11b2 Integrin αM chain Macrophages 
LY6G/LY6C/GR-12 Lymphocyte antigen 6 complex, locus G Granulocytes 
Sca13 Stem cell antigen-1 
Hematopoietic 
stem & progenitor 
cells 
cKit3 Stem cell growth factor receptor 
Hematopoietic 
stem & progenitor 
cells 
 
1LSK refers to lineage negative, Sca1 positive, cKit positive cells 
2Cell types excluded in LSK 
3Cell types included in LSK 
 
Both B and T cells show specificity in responding to foreign antigen but 
differ in how they recognize it. Whereas B cells recognize soluble antigen, T cells 
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can only recognize antigen presented by other cells—bound by the cell surface 
molecule major histocompatibility complex (MHC) which forms a complex with 
the T cell receptor (TCR) on the T cell. While in the thymus, pre-T cells undergo 
selection to ensure that their TCRs can recognize MHC presented by self, 
without reacting too strongly to self (self-tolerance). If the affinity between pre-T 
cell and MHC presentation is not strong enough, the cell is destined to exit the 
thymus as a naïve T cell, since these recognize only foreign proteins. If the 
affinity is too strong, the pre-T cell would be self-reactive, so it is selected against 
and undergoes apoptosis. But if the level of affinity is “just right,” that cell 
becomes a regulatory T cell (Treg cell; Sakaguchi et al., 2008). After selection, T 
cells leave the thymus competent and are able to recognize and react with 
foreign antigen. When in the periphery, the TCR identifies a specific antigen, 
triggering a cascade of events causing an immune response, and at this point the 
T cell is activated. 
Lymphocytes, developing from HSCs, can potentially be affected by 
intrauterine effects resulting in later-life disease. While traditional toxicology looks 
at adult exposures to potentially harmful substances, our research examines how 
developmental exposures to immunotoxicants differ from adult exposures. 
Because hematopoiesis maintains the functional cells of the immune system 
throughout the life course (Seita and Weissman, 2010; Yamada et al., 2013), 
there is a growing recognition that factors that disrupt the balance of HSC self-
renewal and lineage differentiation into immune effector cells can result in 
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immune system diseases (as reviewed in Seita and Weissman, 2010) including 
myeloproliferative disorders and leukemia (K. P. Singh et al., 2013).  
 
 
III. Epigenetics 
 One of the mechanisms proposed to explain DOHaD is epigenetic 
modification (Barouki et al., 2007; North and Ellis, 2011; Susiarjo et al., 2013). An 
organism’s cells each possess a copy of the same DNA, which is the blueprint for 
the organism, written in genes made up of base pairs. At different developmental 
timepoints and in different tissues, genes are turned “on” or “off.” But there is 
evidence that dietary, chemical, or other environmental exposures can impact the 
timing of the expression of genes. Epigenetics provides an explanation of tissue-
specific gene regulation—especially throughout development. Common 
epigenetic alterations include DNA methylation and histone modifications. DNA 
methylation occurs in cytosine rich areas (CpG islands) on regions of DNA, and 
results in inactivation of genes due to an inability of transcription factors to bind 
(Aluru et al., 2011; Mulero-Navarro et al., 2006). Histone modifications include 
acetylation, methylation, phosphorylation, ubiquitination and sumoylation of 
amino acids located on the histones. They, too, result in a change in expression 
of associated genes without an alteration of the DNA sequence. Increasingly, 
epigenetics has come to be accepted as a means by which adult stem cells 
respond to the balance of quiescence and differentiation in mature tissues 
(Rinaldi and Benitah, 2014). However, environmental exposures can alter the 
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epigenetic mechanisms in terms of timing or location of gene expression, and 
improper methylation or histone modification in stem cells can be particularly 
detrimental. Epigenetic alterations in stem cells have been linked to cancer, and 
cancer stem cells have now been identified due in part to their altered ability to 
self-renew and proliferate (Easwaran et al., 2014; Jordan et al., 2006). Additional 
epigenetic alterations, such as methylation changes, have been shown to impact 
both self-renewal and differentiation of HSCs, and alterations have been 
observed in leukemic cell lines (B. Liu et al., 2013; Prasad et al., 2014).  
Developmental epigenetic modifications, such as those induced by 
environmental exposures, affect not only the adult, but offspring and even 
grandchildren of the organism initially exposed (Anway et al., 2005; Burton and 
Metcalfe, 2014). Fortunately, some of these environmentally-influenced 
epigenetic modifications can be altered with diet (Carlin et al., 2013), thus 
illustrating why this research is so important to public health. Dietary 
interventions could be easily incorporated into maternal standards of care, thus 
modulating the environmental damage.  
 
IV. 2,3,7,8 tetrachlorodibenzo-p-dioxin  
TCDD, commonly known as dioxin, has been linked to numerous adverse 
human health effects, including endometriosis (Bellelis et al., 2011), neurological 
and vascular issues (Pelclova et al., 2009), decreased fertility (Eskenazi et al., 
2010), endocrine disruption (Yoon et al., 2014), diabetes (Michalek and Pavuk, 
2008) and cancer (Ansbaugh et al., 2013; Michalek and Pavuk, 2008; Warner et 
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al., 2011). Many of these diseases are immunological in origin, multi-
generational, and potentially result from developmental exposures during 
gestation or the perinatal period (Dietert, 2009; Mustafa et al., 2009, 2008).  
 
A. Structure and Mechanism of TCDD Toxicity 
TCDD exerts its toxicity through a transcription factor known as the 
arylhydrocarbon receptor (AHR). Due to its high binding affinity to AHR (Kd=10-10 
– 10-9M) (Funatake et al., 2005) and because of steric hindrance (Fig. 5), TCDD 
is poorly metabolized (Stevens et al., 2009), and all toxicity is mediated through 
the AHR (Van den Berg et al., 1994) without confounding due to local metabolic 
effects such as inflammation. Though numerous other environmental toxicants 
also activate the AHR, in the laboratory setting TCDD is the most commonly 
used AHR agonist.  
 
Figure 5. The chemical structure of 2,3,7,8-tetrachlorodibenzo-p-dioxin illustrates 
its resistance to metabolism. (image public domain)  
 
 B. Human TCDD Exposures 
TCDD has long been known to be toxic, and most research regarding 
exposures has used animal models. However, a few cases of acute or chronic 
human exposure to TCDD have occurred and these populations have been very 
well studied. 
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Perhaps the best-known case of human TCDD exposure was in Vietnam 
War military veterans who flew aircraft from 1962-71 transporting and spraying 
the herbicide Agent Orange or who worked on the ground where it was used. 
Agent Orange, so named for the orange-colored barrels it was contained in, was 
contaminated with TCDD. A longitudinal health study known as The Air Force 
Health Study has followed veterans of this unit, Operation Ranch Hand, since 
1982 (Pavuk et al., 2005). Among the health outcomes potentially linked to Agent 
Orange exposure are prostate cancer, melanoma, leukemia, malignancy, 
neurological disorders, and immune suppression (Institute of Medicine, 2011; 
Michalek and Pavuk, 2008; Pavuk et al., 2005).  
 In 1976, a chemical manufacturing plant outside of Seveso, Italy 
experienced a factory accident which released high levels of TCDD in the 
neighboring communities (Bertazzi et al., 1998). Some of the health outcomes 
potentially found following the accident include chloracne, neurologic and 
reproductive effects, and changes in liver and immune function (Bertazzi et al., 
1998). Limited information exists on developmental exposures, but Seveso 
cohorts showed connections between TCDD exposure and metabolic syndrome 
in girls exposed pre-pubertally (Warner et al., 2013), and neonatal thyroid 
function impairment 25 years after maternal exposure (Baccarelli et al., 2008). 
There is disagreement on the strength of the epidemiological data 
surrounding human TCDD exposures, due to great variation in the population 
exposed and the concentration and length of time of exposure. Furthermore, 
unlike with animal studies, human epidemiological studies are frequently 
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underpowered. Finally, given the latency period associated with non-fatal 
exposures, many environmental exposures are likely never associated with 
health outcomes. 
 
V. The Arylhydrocarbon Receptor 
AHR, a member of the Per-Arnt-Sim (PAS) superfamily of proteins, is an 
evolutionarily-conserved, basic helix-loop-helix, ligand-activated transcription 
factor responsible for xenobiotic metabolism as well as normal development and 
cell cycle regulation. It promiscuously binds to multiple endogenous and 
exogenous ligands. AHR can be activated by naturally occurring ligands such as 
tryptophan derivatives, bilirubin, prostaglandin G (Stevens et al., 2009) and 6-
shogaol, an extract of ginger (Yoshida et al., 2014). AHR is activated by 
numerous synthetic ligands, such as aromatic hydrocarbons, aromatic amines, 
and indolecarbozoles, which are anthrogenic environmental toxicants (Aluru et 
al., 2011; Beedanagari et al., 2010a, 2010b). It has been hypothesized that the 
ability to bind ligands—especially those created by industry—is a secondary, 
acquired function of the AHR and that its original, evolutionarily conserved 
purpose has yet to be fully elucidated.  
 
 A. Activation by Ligands 
TCDD is the best-characterized ligand of the AHR, and is used in Figure 6 
to illustrate the mechanism by which gene transcription follows AHR activation. In 
the absence of a ligand, AHR binds to the AHR complex (which includes the 
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chaperones heat shock protein 90 (HSP90), protein 23, and hepatitis B virus X-
associated protein) in the cytosol. When bound to ligand such as TCDD, AHR 
dissociates from HSP90, which reveals the AHR’s nuclear localization signal, 
causing a conformational change and allowing entry into the nucleus. In the 
nucleus, AHR heterodimerizes with aryl hydrocarbon receptor nuclear 
translocator (ARNT) via mediation by the PAS domain, and other proteins of the 
complex are removed. The AHR/ARNT heterodimer recognizes DNA binding 
motifs known as arylhydrocarbon response elements (AHREs—also known as 
xenobiotic or dioxin response elements). AHREs are located in the promoter 
region of AHR-responsive genes and binding by the AHR/ARNT heterodimer 
results in differential changes in gene expression, which yield phenotypic 
variation. Some of the pathways triggered by AHR activation include phase I and 
II metabolism, inflammation, and cell cycling (Aluru et al., 2011; Beedanagari et 
al., 2010a, 2010b; Casado et al., 2010; Cui et al., 2009; Stevens et al., 2009).  
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Figure 6. TCDD induces differential gene expression through the AHR pathway. 
The AHR is a bHLH, ligand-activated transcription factor primarily responsible for 
xenobiotic metabolism. Agonists such as TCDD pass through the cell membrane and 
bind to the AHR complex in the cytosol. Binding of the ligand reveals the AHR’s nuclear 
localization signal, causing a conformational change and allowing entry into the nucleus. 
In the nucleus, AHR heterodimerizes with ARNT and other proteins of the complex are 
removed. The AHR/ARNT heterodimer is recognized by DNA binding motifs known as 
AHREs.  
  
 One of the best-studied and most important multi-gene families of 
enzymes that are located downstream of AHR is the cytochrome P450 (CYP) 
family (Beedanagari et al., 2010a, 2010b; Stevens et al., 2009). The CYP family 
is instrumental in metabolizing xenobiotic compounds into intermediary phase I 
compounds, which are then further broken down by members of the glutathione-
S transferase family (GST) and excreted (Fig. 7) (Suter et al., 2010). 
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 The AHR is a principle player in the detoxification pathway of many 
environmental contaminants—specifically the halogenated aromatic hydro-
carbons, such as polychlorinated biphenyls (PCBs), aromatic amines, polycyclic 
aromatic hydro-carbons (PAHs), and other dioxins. Though our research focuses 
on TCDD as the prototypical AHR agonist, the likelihood exists that many other 
environmental contaminants can cause similar responses in the AHR and 
downstream gene cascades. Furthermore, combinations of AHR agonists and/or 
other exposures can act in an additive manner to increase likelihood of disease. 
For example, mice exposed in utero to TCDD and also fed a high fat diet after 
birth were twice as likely to develop mammary tumors than those exposed to 
TCDD in utero but fed a regular diet (La Merrill et al., 2010).  
    
Figure 7. Phase I and Phase II enzymes are involved in detoxification. The 
cytochrome P450 (CYP) enzymes often produce a more toxic intermediate which is 
not readily excretable. Glutathione-S-transferases (GST) will metabolize the toxic 
intermediate into a water-soluble compound which can then be excreted.  
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AHR signaling leads to three different biological pathways—adaptive, toxic 
or developmental (Stevens et al., 2009). In addition to the more familiar 
xenobiotic-induced detoxification, AHR is also associated with maturation, cell 
proliferation, cell cycle control and homeostasis of multiple organ systems, 
including the liver, vascular system, lungs, gastrointestinal and immune system 
(Cui et al., 2009; Mulero-Navarro et al., 2006; Stevens et al., 2009).  
Down-regulation of AHR associated genes can occur by degradation of 
AHR by the ubiquitin/proteosome pathway or via negative feedback by another 
PAS protein known as AHR repressor (AHRR) (Oshima et al., 2009). These 
evolutionarily distinct methods prevent over-activation of AHR associated genes 
(Stevens et al., 2009). However, genes can also be regulated by epigenetic 
mechanisms such as hypermethylation of the promoter region, which has been 
found in both mouse and human cancer cell lines and in samples from human 
acute lymphoblastic leukemia (ALL) tumors (Beedanagari et al., 2010a; Mulero-
Navarro et al., 2006). 
Prenatal exposure to TCDD even prior to implantation has an effect on the 
methylation of some imprinted fetal genes, thus impacting their expression (Wu 
et al., 2004). However, this may be dose-dependent and only observable at 
comparatively high doses (ie: 10 ng/kg/day = 0.01µg/kg/day but not 2ng/kg/day) 
(Somm et al., 2013). Although not directly affecting HSCs, AHR activation does 
epigenetically modify immune cells that are derived from HSCs. Specifically, it 
has been suggested that epigenetic regulation is responsible for a decrease in 
the number of CD4+ T lymphocytes and an increase in the number of Treg cells in 
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adult animals following developmental AHR activation and challenge with 
influenza virus (Boule et al., 2014).  
 
 B. AHR and the Immune System  
AHR is essential for immune development, including regulation of 
hematopoiesis (Casado et al., 2010), induction of auto-immune fighting Treg cells 
(K. P. Singh et al., 2011; Wu et al., 2011), and maintenance of HSCs in the 
quiescent or resting stage (Oguro et al., 2013). In AHR knock-out mice (AHR-/-), 
multiple immunological defects are found, including abnormal HSCs with 
decreased self-renewal potential (K. P. Singh et al., 2011), altered spleen and 
thymus lymphocyte counts (Casado et al., 2010), enlarged spleen in females 
(Esser, 2009), and perinatal extramedullary hematopoiesis in the liver (Harrill et 
al., 2013). Additionally, myeloproliferative hematopoietic diseases are more 
common in mice lacking AHR (K. P. Singh et al., 2013). 
 Though AHR is necessary for regular development, over-activation is as 
detrimental as lack of AHR. Many environmental contaminants that are 
byproducts of combustion exert their toxicity through the AHR. The potent AHR 
agonist TCDD has been linked to numerous poor health outcomes in adult 
animals, including gastrointestinal hemorrhage, liver toxicity, thymic atrophy, and 
death (Sorg, 2013). AHR activation also results in direct immunosuppression 
(Esser, 2009; Hao and Whitelaw, 2013), reduces B cell maturation, and 
increases the severity of some autoimmune diseases (Hao and Whitelaw, 2013). 
Laboratory research has shown suppression of humoral and cellular immune 
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response, increased susceptibility to infection, and thymic involution all following 
TCDD exposure (Stevens et al., 2009). Since the thymus is the site of T cell 
development, the direct effects of thymic involution are thymocyte loss and 
premature thymic emigration of T cells. Therefore alterations in the AHR and 
downstream metabolic target genes of AHR have been implicated as 
susceptibility factors for numerous cancers (Mulero-Navarro et al., 2006) and 
autoimmunity (Stevens et al., 2009).  
Despite the negative health effects connected to adult AHR activation, one 
interesting inconsistency exists. Adult humans and animal models exposed to 
AHR agonists have shown improvement in numerous autoimmune diseases, 
including psoriasis (Di Meglio et al., 2014), Crohn’s disease (Benson and 
Shepherd, 2011), colitis (Furumatsu et al., 2011), Type 1 diabetes (Kerkvliet et 
al., 2009), uveoretinitis (Zhang et al., 2010), and a murine model of multiple 
sclerosis (Hamza and Abdullah, 2013). The mechanism by which AHR activation 
in adult murine models improves autoimmune disease symptoms involves Treg 
cells (Benson and Shepherd, 2011; Funatake et al., 2008; Gandhi et al., 2010; 
Marshall and Kerkvliet, 2010; Mezrich et al., 2010; Zhang et al., 2010). 
Conversely, exposure to AHR agonists during fetal development has shown that 
prenatal AHR activation by TCDD increases immune disorder (Gogal and 
Holladay, 2008; Holladay et al., 2011; Mustafa et al., 2009), specifically leading 
to a loss of tolerance in later life.  
Given the paradox in disease outcomes related to the AHR and the 
potential for benefits following AHR activation, a recent focus of research 
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involves non-toxic dietary AHR agonists such as those derived from Lactobacillus 
bulgaricus (Takamura et al., 2011), resveratrol (Rimmelé et al., 2014) and 
multiple tryptophan derivatives (Bock, 2013). These endogenous ligands differ 
most notably from TCDD in their transient activation of the AHR. These and other 
non-toxic AHR agonists have shown promise in combatting both autoimmune 
and inflammatory diseases (Busbee et al., 2013).  
 In addition to an increase in autoimmunity, developmental AHR activation 
has been linked to impairment of multiple cell-mediated immune functions 
(Holladay and Smialowicz, 2000) including response to influenza infection (Boule 
et al., 2014; B A Vorderstrasse et al., 2004). In mice, while exposure to TCDD 
throughout gestation and lactation does not initially affect T cell ratios, when the 
same mice were infected with influenza, the frequency of CD4+ Treg cells 
increased and activated CD4+ T cells decreased (Boule et al., 2014). Similarly, in 
humans, maternal AHR activation has been linked to immunosuppressive 
response to measles vaccine in offspring three years later (Hochstenbach et al., 
2012). Given the drop in vaccination rates in developed countries for non-medical 
reasons, adding a similar drop in vaccine effectiveness due to environmental 
exposures could allow a return of many nearly eradicated diseases. 
 Furthermore, while adult AHR activation results in transient immune 
effects, developmental activation has been linked to more persistent functional 
effects (Hogaboam et al., 2007). This emphasizes the importance of timing of 
AHR activation—the specifics of which have yet to be fully elucidated.  
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 AHR is just one of the signaling pathways involved in immune system 
development and maturation. Pathway crosstalk is common, and the AHR is 
known to crosstalk with pathways including protein kinases (Esser et al., 2009), 
which are important for immune system regulation and function. Furthermore, 
dysregulation in protein kinases has been linked to disease development, 
including leukemia and myeloproliferative neoplasms (Gery and Koeffler, 2013). 
Discovery of additional pathway crosstalk with AHR could help explain the recent 
increase in immune disorders. 
 
VI. Notch 
Notch is necessary for direct cell-to-cell contact involved in regulation of 
cell development in the embryo and during adulthood. Notch proteins are highly 
conserved receptors found on the cell surface (Fig. 8) (Alam et al., 2010; 
Borggrefe and Oswald, 2009; Osborne and Minter, 2007; Schmitt and Zúñiga-
Pflücker, 2002). The four Notch proteins (Notch 1, 2, 3, & 4) have been found in 
all animal species to date (Lai, 2004). The Notch ligands in vertebrates are made 
up of members of the Jagged (Jagged 1 & 2) and Delta-like (DL1, DL3, DL4) 
families. Both the receptors and the ligands are single-pass transmembrane 
proteins and each possess an extracellular epidermal growth factor (EGF) 
repeating motif necessary for direct contact mediation between the two 
(Ferrando, 2009; Lai, 2004).  
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 A. The Notch Signaling Pathway  
It has been suggested that AHR-mediated environmental signals can 
contribute to over-stimulation of Notch, resulting in tumors, T cell acute 
lymphoblastic leukemia lymphoma (T-ALL), and other cancers (Alam et al., 
2010).  
The thymus is rich in Delta-like Notch ligands (Zúñiga-Pflücker, 2004) 
which play a role in hematopoietic cell fate decisions. Ligands such as DL1 
interact with the extracellular portion of Notch. In addition to the extracellular, 
EGF-rich portion, Notch also has an intracellular portion (ICN). The intercellular 
domain is responsible for binding to transcriptional repressor CBF1-suppressor of 
hairless-Lag1 (or CSL). Even before encountering ligand, Notch receptors 
undergo activation in preparation for signaling. Notch receptors are housed in the 
endoplasmic reticulum in an inactive form. In the Golgi complex, the receptor is 
constitutively cleaved by a furin-like protease, forming a non-covalently bound 
heterodimer composed of the extracellular and intercellular portions, and 
reassembled into a cell surface receptor (Lai, 2004). The extracellular portion is 
then glycosylated (Osborne and Minter, 2007).  
When a Notch receptor on a lymphocyte progenitor physically interacts 
with a Notch ligand such as a Delta-type ligand present on a stromal cell, EGF 
repeats on the ligand interact with the Notch receptor and trigger the second 
cleavage—which results in release of the extracellular portion of Notch. The third 
step involves cleaving of ICN by gamma secretase (Schmitt and Zúñiga-Pflücker, 
2002), which allows the ICN to travel to the nucleus, where it associates with a 
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constitutive CSL transcription factor (CBF1-Su(H)-LAG-1 in humans; RBP-J in 
the mouse), as a co-activator which drives T cell commitment (Borggrefe and 
Oswald, 2009; Lai, 2004; Osborne and Minter, 2007; Pajerowski et al., 2009). 
CSL is associated with co-repressors when Notch is not present, which prevent 
Notch target gene transcription (Lai, 2004) and drive B cell commitment 
(Osborne and Minter, 2007; Zúñiga-Pflücker, 2004). ICN, upon association with 
the co-activators, recruits transcriptional co-activators from the mastermind-like 
(MAML) family, which allow the expression of Notch target genes (Pajerowski et 
al., 2009). MAML1 may also serve to mediate early T cell development, as it has 
been shown in vitro to increase phosphorylation and subsequent Notch receptor 
degradation when combined with CSL (Osborne and Minter, 2007).  
Several Notch target genes have been identified to date. These include 
the highly evolutionarily conserved hairy/enhancer of split (HES) family—basic 
helix-loop-helix (bHLH) proteins, which are essential for T cell development and 
signaling, and a related family—HES with YRPW motif (HEY—also known as 
HERP). Both HES and HEY members can be activated by constitutive Notch1 
and act as transcriptional repressors. HES1 and HES5 over-expression also 
inhibits B cell development. In addition to T cell development and signaling, 
Notch target genes have been associated with T cell activation, proliferation, 
cytokine production and protection from apoptosis (Osborne and Minter, 2007).  
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Figure 8. Notch activation by ligands induces differential gene expression driving 
T cell commitment. The Notch receptors are composed of an extracellular portion with 
EGF repeats, and an intercellular portion. When the EGF repeats on a Notch ligand 
(Delta or Jagged families) contact the extracellular portion of a Notch receptor, gamma 
secretase is responsible for lysis of the intercellular (NICD) portion of Notch. NICD then 
moves into the nucleus of the cell where it interacts with a CSL (RBP-J in the mouse) co-
activator to drive expression of genes, including those involved in T cell commitment.  
 
 
 While Notch is also involved in development of CD4+ and CD8+ single 
positive (SP) T cells from CD4+CD8+ double positive (DP) precursor thymocytes, 
the definitive link between Notch signaling and T cell development concerns the 
T cell vs. B cell fate decision at the progenitor step of development.  
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 B. In vitro Culture of T cells, Using Notch 
Early lymphocyte differentiation research most often focused on B cells 
because they were relatively easy to grow in the lab from HSCs in a co-culture 
system with murine bone marrow stromal cells. Since B cells differentiate in the 
bone marrow, these stromal cells provided all the signaling needed for 
maturation from HSC to effector B cells. However, T cells differentiate in the 
thymus, and until 2002, the only way to model HSC differentiation into T cells 
was by using the much more involved fetal thymic organ culture (FTOC). While it 
was known that Notch played a necessary role in T cell commitment, the 
component of the Notch pathway that could be isolated from the thymus and 
used to help grow T cells in vitro was still unknown. 
Schmitt and Zúñiga-Pflücker were the first to successfully engineer a cell 
line that could support the commitment, development, and growth of T cells in the 
lab (Schmitt and Zúñiga-Pflücker, 2002; Zúñiga-Pflücker, 2004). They began with 
the bone marrow stromal cell line derived from OP/OP mice (and therefore 
named OP9) which had previously been used to support the growth of B cells 
and NK cells from both bone-marrow derived HSCs and also from embryonic 
stem cells (ESCs). Both OP9 cells and thymic stromal cells were found to 
transcribe Jagged-1 and Jagged-2, but only the thymus transcribed Delta-like-1 
and Delta-like-4.  
Schmitt and Zúñiga-Pflücker developed a line of OP9 stromal cells which 
were retrovirally transduced to express the Notch ligand Delta-like-1. The 
resulting cell line was named OP9-DL1. The OP9-DL1 stromal cell line and an 
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OP9-GFP non-Delta-like-1 expressing control stromal line were used to test the 
growth of hematopoietic progenitor cells (HPCs). LSKs harvested from fetal livers 
were co-cultured on both OP9 cell lines in the presence of interleukin-7 (IL-7) and 
Fma-related tyrosine kinase 3 (FLT3) ligands (Schmitt and Zúñiga-Pflücker, 
2002; Zúñiga-Pflücker, 2004). Development was followed via flow cytometry 
analysis for up to 17 days (Fig. 9).  
 
 
Figure 9. The OP9-LSK co-culture system includes bone marrow stromal cells and 
HSCs. A) LSK cells isolated from GD14.5 fetal livers are grown in co-culture with OP9 
bone marrow stromal cells in the presence of FLT3-L and IL-7 for 12 (T cell) or 14 (B 
cell) days. B) Mature lymphocytes grown in co-culture with OP9 bone marrow stromal 
cells.  Cells were harvested from co-culture and analyzed by flow cytometry for B or T 
lineage development. 
 
The control OP9-GFP cells resulted in mature B cells and natural killer 
(NK) cells starting on day 4 and continuing through day 12, and did not produce 
any T cells. However, the LSKs cultured on OP9-DL1 cells gave rise to DP 
immature T cells starting on day 7 and developing through day 12 (Schmitt and 
Zúñiga-Pflücker, 2002). The pattern of development follows that of HSCs in 
FTOC, including maturation from double negative (DN; CD4-CD8-) to double 
LSK cell 
Lymphocyte 
OP9 stromal cell 
12-14 
days 
FLT3-L 
IL-7 
A. 
B. 
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positive (DP; CD4+CD8+) and single positive (SP; CD4+ or CD8+) T cells, as 
well as generation of both ɣδ-TCR and αβ-TCR T cells. In addition, the T cells 
grown were found to be functionally mature, as they produced IFNɣ when 
stimulated by CD3 and TCR (Schmitt and Zúñiga-Pflücker, 2002). Finally, the 
HSCs were obtained from mouse fetal livers, which are considerably larger and 
easier to obtain than the fetal thymus. Chapters three and four of this dissertation 
rely on the OP9 co-culture system to measure HSC differentiation potential.  
 
 C. Notch in T-ALL 
Notch mutations have been correlated with the occurrence of T cell acute 
lymphoblastic leukemia (T-ALL) (Ferrando, 2009; Gordon et al., 2009; Kumar et 
al., 2014; N. Liu et al., 2013; Paryan et al., 2013; Tosello and Ferrando, 2013; 
Weng et al., 2004). Over half of the diagnosed cases of T-ALL have activating 
Notch1 mutations. Overexpression of the intracellular portion of Notch1 (ICN) 
drives CD8+ commitment at the expense of CD4+ commitment and transgenic 
mice that overexpress ICN are prone to T cell thymic tumors (Fowlkes and 
Robey, 2002). We use thymocyte specific lck-proximal promoter over-expressing 
ICN transgenic mice in the experiments described in chapter five. 
 
VII. Study Rationale 
 Given that the AHR has been linked to immunological disease in adult 
models and it is recognized that developmental exposures are frequently more 
detrimental due to impact on stem cells, we hypothesized that developmental 
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exposure to AHR agonists such as TCDD alter HSCs in a manner that negatively 
impacts later-life immunity. 
An organism’s time in utero is developmentally unique, as it transforms 
from a fertilized egg into a multi-cellular organism. The initial multi-potent stem 
cells, able to differentiate into all types of cells, gradually become committed to 
particular lineages, such as the hematopoietic lineage. Because the directions for 
development of the mature immune system is directed by DNA  in the HSCs, any 
resulting impact on HSCs during gestation—such as the failure to differentiate 
correctly—can reprogram the genetic code, leading to immunodeficiencies later 
in life. The immune system formed from imperfect HSCs may exhibit 
immunosuppression (an insufficient ability to fight infection), may not correctly 
develop self-tolerance (resulting in autoimmunity), or may not balance 
replenishment and differentiation correctly (resulting in cancer). The overall goal 
of this research was to determine what role developmental exposure to AHR 
agonists such as TCDD has on later-life immunity. 
 The effect that developmental exposure to TCDD has on the ability of 
HSCs to differentiate into lymphocytes was determined using a novel limiting 
dilution analysis assay. HSCs were isolated on GD14.5 from fetal livers of 
C57BL/6 mice exposed to either vehicle control or 3µg/kg TCDD throughout 
gestation. HSCs were co-cultured with OP9 bone marrow stromal cells and the 
ability to differentiate into B or T lymphocytes was measured using Extreme 
Limiting Dilution Analysis (ELDA) for stem cell research (Hu and Smyth, 2009). 
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Developmental TCDD exposure was found to decrease by two and a half fold the 
ability of HSCs to become mature B cells or thymocytes. 
 Given that TCDD is the most potent AHR agonist known, we hypothesized 
that developmental TCDD exposure induces differentiation effects by fetal AHR 
activation. The role that fetal AHR plays in HSC development after gestational 
exposure to TCDD was determined by repeating the limiting dilution assay using 
HSCs from transgenic mice lacking an AHR. We found that AHR in the fetus is 
responsible for the effects caused by developmental TCDD exposure, which 
results in a decrease in the potential of HSCs to differentiate into mature 
lymphocytes. Mice lacking an AHR do not experience the TCDD-induced 
decreased thymocyte differentiation effect. 
The role that developmental exposure to TCDD plays in T cell 
development in adults was determined using transgenic mice that overexpress 
Notch1, which is implicated in over half the cases of T-ALL. Notch has been 
associated with the maintenance of undifferentiated HSCs (Zhou et al., 2010) 
and is downregulated as HSCs differentiate (Duncan et al., 2005). We exposed 
Notch transgenic mice to TCDD throughout gestation and lactation, then followed 
the mice through adulthood, tracking blood cell phenotype weekly. We found that 
the crosstalk between AHR, as developmentally activated by TCDD, and later 
Notch1 signaling does not act in an additive manner, but rather in what appears 
to be a competitive manner, resulting in more typical T cell ratios and better 
health outcomes in the transgenic mice developmentally exposed to TCDD. 
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 These studies contribute significantly to our knowledge of the AHR during 
development, the effect of environmental insult on genetically-susceptible 
populations, DOHaD specific to the immune system, and the mechanism by 
which these effects occur. This research provides an important contribution to 
public health because of the need to elucidate reasons for increasing disease 
rates in order to drive policy and to develop preventative health strategies 
(Barouki et al., 2012). Prevention plays a critical role because unlike 
polymorphisms such as BRCA1, epigenetic alterations are reversible with dietary 
interventions (Carlin et al., 2013).  
 While research findings support the impact of dioxin-like chemicals as 
factors increasing immune disorders, and efforts are being made to decrease 
environmental contaminants, the genetic component is equally important to 
complete understanding of this health crisis. Given that the increase in immune 
disorders is likely the result of a combination of genetic and environmental 
causes (Faulk and Dolinoy, 2011), determining at which stage(s) developmental 
AHR activation causes immune dysfunction would allow clinical intervention at an 
early time point. The ability to test stem cells for genetic or epigenetic alterations 
could identify susceptible populations and focus potential preventative efforts at 
an early stage in particularly vulnerable people and to counsel patients at risk on 
avoiding additional risk factors. Furthermore, elucidating the genetic aspect of 
susceptibility provides a therapeutic focus (Quintana, 2012).  
Finally, an underdeveloped immune system can not only increase 
development of immune-related diseases, but also result in an immune system 
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less likely to respond favorably to immunization (Hogaboam, Moore et al. 2008). 
Though public health practice aims for 100% immunization, in order for effective 
population immunity, vaccination rates need only meet the herd immunity 
threshold, which varies depending on the vaccine and population (Fine et al., 
2011). However, even if the threshold is reached, if not all vaccinated are 
achieving full immunity from vaccines due to deficient immune systems, a public 
health crisis could emerge.  
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CHAPTER 2 
 
 
 
 
 
MATERIALS AND METHODS 
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Solutions and Buffers 
MEM: Minimum Essential Medium alpha (α-MEM; Life Technologies, 
Carlsbad, CA); 1 packet, combined with 2.2 g NaHCO3, topped off with 1 L 
ddH2O, stirred for 10 minutes and filter sterilized using a 0.2µm filter (aPES 
membrane), then stored at 4oC in the dark. 
OP9 media: MEM supplemented with 20% FBS (lot tested for supporting 
OP9 co-cultures; Life Technologies) and 0.05mg/mL gentamycin (Life 
Technologies), filter sterilized and stored at 4oC in the dark. 
DMEM complete: Dulbecco’s Modified Eagle Medium (Mediatech, 
Manassas, VA); supplemented with 10% fetal bovine serum (FBS; Invitrogen, 
Grand Island, NY), 1% L-glutamine (Invitrogen), 1% 1 M HEPES (Invitrogen), 
0.01% 0.5 M 2-Mercaptoethanol (EMD, Gibbstown, NJ), and 0.001 mg/mL 
gentamycin (Life Technologies), filter sterilized and stored at 4oC in the dark. 
Serum-free DMEM: Dulbecco’s Modified Eagle Medium (Mediatech); 
supplemented with 1% L-glutamine (Invitrogen), 1% 1 M HEPES (Invitrogen), 
0.01% 0.5 M 2-Mercaptoethanol (EMD), and 0.001 mg/mL gentamycin (Life 
Technologies), filter sterilized and stored at 4oC in the dark. 
FACs buffer: Fluorescence activated cell sorting buffer; consisting of 
Hank’s buffered saline solution (HBSS; Corning CellGro, Herndon, VA), 
supplemented with 0.5% FBS (Invitrogen) and 0.1% sodium azide (J.T. 
Baker/Avantor, Center Valley, PA), then stored at 4oC in the dark. 
RBC lysis buffer concentrate: Red blood cell lysis buffer, consisting of  
8.02 g (155 mM) NH4Cl (ammonium chloride) + 0.84 g (12 mM) NaHCO3 (sodium 
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bicarbonate) + 0.37 g (0.1 mM) EDTA (10X concentration), then filled to 100ml 
with Millipore water. Diluted 1:10 before use. 
 
Experimental Animals 
All animal procedures were conducted according to NIH’s Guide for the 
Care and Use of Laboratory Animals (National Research Council, 2011) and with 
the approval of the Institutional Animal Care and Use Committee (IACUC) at the 
University of Wisconsin-Milwaukee. C57BL/6J (B6) and B6.129-Ahrtm1Bra/J (AHR) 
mice used were obtained directly from the Jackson Laboratory (Bar Harbor, ME), 
or were offspring from original Jackson mice. Due to reproductive deficiency of 
AHR-/- females, this strain was maintained by either HZ x HZ (AHR+/- x AHR+/-) 
or KO (AHR-/-) male x WT (C57BL/6J; AHR+/+) female pairings. C57BL/6-
Tg(LckNotch1)9E mice, hereafter referred to as Notch1ICN-TG mice, were offspring 
of original pups that were a generous gift from B.J. Fowlkes, PhD, at the National 
Institute of Allergy and Infectious Disease (NIAID), Bethesda, MD. These mice 
were maintained as homozygous stock prior to breeding to C57BL/6 to generate 
heterozygous Notch1ICN-TG used for all experimental procedures.  
After overnight pairings, the presence of a vaginal mucus plug was used 
as evidence of mating and designated “gestational day (GD) 0.5.” For breeding 
resulting in live birth offspring, mice were placed together for 4-7 days and 
checked for presence of vaginal plug each morning. However, for time-sensitive 
breeding, animals were placed together between 3:00 pm and 5:00 pm and 
presence of vaginal plug was determined between 7:00 am and 9:00 am the next 
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morning to ensure that fetuses were as close to similar developmental age as 
possible. This was a change in protocol from week-long breeding periods as it 
was determined that fetuses from the same day vaginal plug observations still 
appeared varied in size and developmental stage. 
For breeding resulting in live birth offspring after gestational exposure to 
TCDD, all multiparous mothers were used. This change in protocol came about 
due to a high percentage of neonatal deaths, possibly due to either a lack of 
mothering experience or a failure of mammary gland differentiation after 
exposure to TCDD (Lew et al., 2009; Beth A Vorderstrasse et al., 2004).  
All mice were housed in micro-isolator cages in a specified pathogen-free 
facility at the University of Wisconsin-Milwaukee, provided food and water ad 
libitum, and maintained on a 12:12-h light cycle.  
 
Genotyping of Transgenic Mouse Strains 
Tissue samples were collected as ear punches from adult mice and tail 
samples from fetal mice. Ear tissues were digested with rotation at 55oC 
overnight in 190µl DirectPCR Lysis Reagent (ViaGen Biotech, Los Angeles, CA) 
plus 10 µl Proteinase K (ViaGen Biotech). Fetal tail tissues were digested in 
160µl Direct PCR lysis buffer plus 40 µl Proteinase K for 20 minutes with 
intermittent vortexing in a locking-cap 1500µl microcentrifuge tube (Eppendorf, 
USA). Proteinase K in samples tubes was then inactivated for one hour at 85oC 
(ear) or a 1:5 diluted sample for 20 minutes at 95oC (fetal tail). Primers (Table 2) 
were thawed over ice. Reaction samples were mixed, each containing 12.5µl 
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MyTaq, 0.5µl each primer, 9.5µl DNAse free water, and 2 µl of genomic DNA. 
Samples were run in thermocycler according to specifications listed in Table 3.  
 
 
Table 2. qPCR SybrGreen primers used 
Gene 
name 
Direction Sequence 
AHR 
forward CAGTGGGAATAAGGCAAGAGTGA  
reverse AGGGAGATGAAGTATGTGTATGTA 
HgH 
forward CAACAGGGAGGAAACACAACAG 
reverse GTTTGGATGCCTTCCTCTAGGT 
SrY 
forward TCATGAGACTGCCAACCACAG 
reverse CATGACCACCACCACCACCAA 
Myog 
forward TTACGTCCATCGTGGACAGC 
reverse TGGGCTGGGTGTTAGTCTTA 
 
 
Table 3. Thermocycler specifications 
Gene 
name 
Stage Temp Time Note 
AHR 
1 95oC 3 min.  
2 
95oC 5 sec. 
Repeat 
stage 2 for 
30 cycles 
58oC 5 sec. 
72oC 10 sec. 
3 
72oC 5 min. 
Hold 
4oC - 
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HgH 
1 94oC 5 min.  
2 4oC 
 
30 sec. 
Repeat 
stage 2 for 
35 cycles 
63oC 
 
1 min. 
72oC 1 min. 
3 72oC 7 min. 
Hold 
4oC - 
Sry  
&  
Myog 
1 94oC 3 min.  
2 
94oC 5 sec. 
Repeat 
stage 2 for 
30 cycles 
57oC 5 sec. 
72oC 15 sec. 
3 
72oC 1 min. 
Hold 
4oC - 
 
PCR samples were run on a 2.2% Lonza FlashGel single tier DNA 
cassette (Lonza, Allendale, NJ) at 225 V for 15-20 minutes, while MovieMaker 
(Microsoft, Redmond, WA) ran continuously, recording band migration. 
 
TCDD Preparation and Treatment Protocol 
TCDD (Cambridge Isotopes, Andover, MA) was diluted in 1,4-dioxane 
(Sigma-Aldrich, St. Louis, MO) to a working stock concentration of 0.2 mg/ml. 
Appropriate volume of TCDD in 1,4-dioxane was subsequently transferred to a 
sterile 15 ml conical tube and the liquid was evaporated in a chemical fume hood. 
The remaining TCDD residue was then suspended in olive oil (Filippo Berio, 
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Hackensack, NJ) to a concentration of 0.3µg/ml, 1.0µg/ml or 3.0µg/ml and was 
mixed by rotation overnight at room temperature. For dosing of vehicle control 
mice, olive oil was added to a tube from which an equal volume of 1,4-dioxane 
had been evaporated.  
For experiments where LSKs were isolated from GD 14.5 fetal livers, 
pregnant mice in the treatment group were exposed to either 3µg TCDD/kg body 
weight by oral gavage on gestational days 0.5 and 7.5, or olive oil vehicle control 
(0.1ml per 10g) on the same days. Doses were given 7 days apart to insure a 
relatively constant level of TCDD throughout because the half-life of TCDD in a 
C57BL/6 mouse is approximately one week (Gasiewicz et al., 1983; Hogaboam 
et al., 2007; Miniero et al., 2001; Weber and Birnbaum, 1985).  
For experiments where developmentally-exposed mice were allowed to 
grow to adulthood, pregnant mice in the treatment group were given 3µg 
TCDD/kg body weight by oral gavage on GDs 0.5, 7.5, 14.5, and post-partum 
day (PPD) 2.5, while the control mice received an equivalent volume of olive oil 
(0.1ml per 10g) on the same days. This dosing regimen included not only in utero 
exposure, but also lactational exposure, mimicking the pattern of exposure in the 
environment. Such methodology was chosen to accurately represent 
environmental exposure as TCDD has been found to be more detrimental when 
maintained throughout development (Hogaboam et al., 2007).  
For some experiments rather than a developmental exposure, four week 
old naïve mice were exposed to a single dose of 10µg or 30µg TCDD/kg body 
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weight or an equal volume of vehicle control (0.1 ml per 10g) by oral gavage and 
tissues were analyzed 10 days after exposure. 
 
Antibodies Used for HSC/HPC and Lymphocyte Staining 
Primary fluorochrome-conjugated monoclonal antibodies were used in 
flow cytometry analysis and cell sorting (Table 4) on a BD FACSAria III, DIVA 
version 6.1.3. 
Table 4. Monoclonal antibodies, clones and fluorochromes used in 
fluorescence activated cell sorting and flow cytometry analysis  
Antibody Clone Fluorochrome* 
B220 RA3-6B2 PE 
CD3 145-2C11 biotin 
CD3 145-2C11 PE-CF594 
CD4 RM4-5 APC-H7 
CD4 RM4-5 PECy5 
CD4 RM4-5 PE 
CD5 53-7.3 biotin 
CD11b M1/70 biotin 
CD11b M1/70 Alexa488 
CD19 1D3 FITC 
CD25 7D4 biotin 
CD44 IM7 PECy5 
CD45 30-F11 PE 
CD45R/B220 RA3-6B2 biotin 
CD8α 53-6.7 PE-Cy7 
CD8α 5H10 Alexa647 
cKit1 2B8 Alexa647 
GR-1 RB6-8C5 APC-Cy7 
LY-76 TER119 biotin 
LY6G/LY6C/GR-a RB6-8C5 biotin 
Sca-1 E13-161.7 PE 
Streptavidin - FITC 
Streptavidin - PE-TR 
 
*FITC=fluorescein isothiocyanate; PE=phycoerythrin; Cy=cyanine; APC=allophycocyanin; 
TR=Texas Red 
1Purchased from Life Technologies 
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HSC/HPC populations were identified by the absence of lineage markers 
(CD3, LY-76, CD45R/B220, CD11b and LY6G/LY6C/GR-a1) and presence of 
two stem cell markers (Sca-1 and cKit).  
Immature thymocytes and B cells resulting from OP9 co-culturing were 
identified based on expression of CD8α, CD4, CD25, CD44, B220 and CD19.  
Weekly blood and tissue cells were identified based on expression of 
CD19, CD11b, CD45, CD3, CD4, CD8 and GR-1. Tumor cells were identified by 
the presence of CD5 after gating on CD3+ populations and within CD4+ or CD8+ 
subsets.  
For thymocyte and splenocyte cellular analysis, living cells were first 
identified by staining with 10µl of the vital dye Sytox Blue (Life Technologies), 
1mM, diluted 1:80, to label nuclei from dead or dying cells with permeable 
membranes. Sytox Blue negative cells were then identified by the presence of 
CD4 and/or CD8.  
For adult high-dose exposures, total cellularity was determined by dilution 
in viable cell determining trypan blue and manual counting using a 
hemocytometer (Fisher Scientific, Pittsburg, PA). Cells were then identified by 
the presence of CD4, CD8, CD44, CD3 and CD25.  
For cell-cycle experiments, co-cultures were incubated in the presence of 
10 mM 5-bromo-2’-deoxyuridine (BrdU) for one hour prior to harvest. Cells were 
then stained with appropriate surface markers followed by fixation and 
permeabilization using the BD FITC BrdU flow cytometry kit according to the 
manufacturer’s instructions (BD Biosciences). Thymocyte precursors were 
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identified by the presence of both CD4 and CD8α surface markers. B cell 
precursors were identified by presence of both B220 and CD19 surface markers. 
All antibodies were used at titrated concentrations and were purchased 
from BD Biosciences unless otherwise noted. 
 
Fetal Liver HSC Isolation and Cell Sorting 
Pregnant C57BL/6J or AHR+/- mice were euthanized by CO2 asphyxiation 
according to the AVMA Guidelines on Euthanasia (AVMA, 2013) on GD 14.5. 
Dissections and tissue harvest were carried out within a 2 hour window (7:00 am-
9:00am CST) each day to minimize time-of-day fluctuations in HSC numbers (K. 
P. Singh et al., 2011). Fetuses were removed to culture dishes containing cold 
DMEM complete media.  
For all HSC experiments, fetal livers were removed from individual 
fetuses, mechanically dispersed in DMEM complete, and passed through sterile 
Nitex nylon mesh (80µm; Wildco, Yulee, FL) to form single-cell suspensions. 
Mature fetal liver cells were eliminated by CD24-mediated (clone J11d.2) 
complement-dependent lysis with low tox Rabbit Complement (Cedarlane, 
Burlington, NC) at 37oC for 30 minutes with gentle agitation. After centrifugation 
at 300 g for 5 minutes, pellet was then re-suspended in serum-free DMEM and 
depleted of dead cells by centrifugation over Lympholyte Mammal (Cedarlane) at 
800g for 20 minutes (Carlyle and Zuniga-Pflucker, 1998). Remaining cells were 
harvested from the buffy layer, washed three times in DMEM complete, and 
sorted.  
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Sorting of hematopoietic stem cells was first based on the absence of 
mature lineage markers in a cocktail of antibodies including CD3, LY-76, B220, 
CD11b and GR-1, as described above. Lineage negative (Lin-) cells were further 
identified by the presence of Sca-1 and cKit, also described above.  
Cells were sorted on a BD FACSAria III, DIVA version 6.1.3, equipped 
with four laser (violet 407 nM, blue 488 nM, yellow/green 561 nM and red 633 
nM), four way sorting capacity and an automated cell deposition unit capable of 
sorting a single cell into an individual well on a 96 well tissue culture plate. Just 
prior to cell sorting, 10µl of the vital dye Sytox Blue (Life Technologies), 1mM, 
diluted 1:80, was added to label nuclei from dead or dying cells with permeable 
membranes. Sytox Blue negative cells were electronically gated on the 407 violet 
B detector. Subsequently, doublets were excluded using FSC Height X Width 
and SSC Height x Width discrimination. Lin- cells were detected on the Blue B 
detector with a 502LP mirror and 530/30 filter. Sca-1+ cells were detected on the 
yellow-green D detector with a 582/15 filter set. c-Kit+ cells were detected on the 
Red B detector with a 660/20 filter set. Lineage-Sca-1+cKit+ (LSK) cells were 
directly sorted into individual wells on a Costar tissue culture treated 96 well plate 
(Corning, Corning, NY) at concentrations ranging from 1-30 cells per well, or 
sorted into a single tube and then divided into aliquots of 4000 cells per well in a 
24 well plate (Corning). Both 96- and 24-well plates were pre-seeded with 
mitomycin C treated OP9-GFP or OP9-DL1 adherent bone marrow stromal cells 
at 75-85% confluency (described below).  
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Blood and Tissue Harvest and Analysis 
For analysis of immune cell ratios, mice were weighed and blood was 
harvested weekly, beginning at 5 weeks of age and ending at 12 weeks of age. 
For maxillary blood collection, mice were restrained by hand, then the right cheek 
was nicked with a 5 mm Goldenrod animal lancet (Medipoint, Inc., Mineola, NY). 
Approximately 100µL of blood was collected from the maxillary vein and 
deposited into a 2000µL microcentrifuge tube (Eppendorf) containing 50 µL of 
heparin (Sagent Pharmaceuticals, Schaumburg, IL). 
100µL of blood/heparin were washed in 1 ml Hank’s buffered saline 
solution (HBSS; Corning CellGro), supplemented with 0.5% FBS (Invitrogen) and 
0.1% sodium azide (J.T. Baker/Avantor). Prior to analysis, Fc receptors were 
blocked with 2.4G2, red blood cells were lysed with BD Pharm Lyse (BD 
Biosciences) and then cells were stained and analyzed for surface expression of 
CD4, CD8, CD19, CD11b, CD-3, Gr-1 and CD45 (see antibody section for 
details). Because CD4+CD8+ cells are normally found only in the thymus, any 
blood samples with populations of CD4+CD8+ were eliminated from our analyses 
(Fig. 10). 
Throughout the experiment, tissue samples were harvested from mice at 
varying times. Mice were observed daily, and if a mouse appeared visibly ill 
(slow-moving, apparent tumor growth), it was euthanized by CO2 inhalation 
followed by cervical dislocation according to the AMVA guidelines (AVMA, 2013). 
For some experiments, half of the mice were euthanized at week 8, and all 
remaining mice were euthanized at completion of the experiment on week 12. 
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After euthanasia, spleen and thymus were removed from individual mice, 
mechanically dispersed in HBSS (Corning CellGro), supplemented with 0.5% 
fetal bovine serum (Invitrogen) and 0.1% sodium azide (J.T. Baker/Avantor), and 
passed through sterile Nitex nylon mesh (80µm; Wildco, Yulee, FL) to form single 
cell suspensions. The cells were then depleted of red blood cells with lysis buffer, 
Fc blocked with 2.4G2, then stained and analyzed for surface expression of CD3, 
CD4, CD8, CD11b, and CD5.  
                     
 
 
Figure 10. One measure of sickness in mice is presence of DP (CD4+CD8+) cells in 
peripheral blood. A) Flow cytometry plot of blood illustrating normal DP population; B) 
Flow cytometry plot of blood illustrating DP population in excess of 2.5%; Mice 
resembling B were eliminated from our analysis of bloods based on sickness, with DP 
cells indicating presence of a metastatic thymoma. Figure originally included as 
supplementary for Chapter 5 manuscript. 
 
Placenta Harvest and Histology 
Placentas were placed individually into processing/embedding cassettes 
(VWR, West Chester, PA) and preserved in 10% Neutral Buffered Formalin 
(VWR) for 48-72 hours, then transferred to 70% EtOH (Pharmco-AAPER, 
Brookfield, CT). Sample mounting and hematoxylin and eosin (H&E) stain were 
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completed at the CRI Histology Core Facility at the Medical College of 
Wisconsin, Milwaukee, WI. Slides were examined by a minimum of two readers, 
and areas of labyrinth and total placenta were calculated using ImageJ software 
(Schneider et al., 2012), following published guidelines (Susiarjo et al., 2013).  
 
In vitro LSK Short-Term Self-Renewal Assay 
LSK cells were sorted as described above, and cells were placed in 
StemSpan SFEM serum free media (Stem Cell Technology, Vancouver, BC, 
Canada) supplemented with 100 ng/ml SCF (Peprotech). Five hundred cells per 
well in multiple wells on a 96 well plate were seeded on day 0 with feeding of 
fresh media and SCF occurring every two days. On days 3, 6, 9, 12, and 15, cells 
were harvested in quadruplicate, stained for lineage and hematopoietic stem cell 
surface markers as described above, and cells were acquired on the FACS Aria 
III. Cell counts were obtained on the flow cytometer using counting beads (Life 
Technologies) according to the manufacturer’s instructions.  
 
OP9 Co-Culture System 
OP9 bone marrow-derived stromal cells transduced with either GFP (OP9-
GFP) or Notch ligand delta-like 1-GFP-IRES (OP9-DL1) were a generous gift 
from Dr. Juan Carlos Zúñiga-Pflücker (Department of Immunology, University of 
Toronto, Sunnybrook, Ontario, Canada). From original cell lines, cells were 
expanded and then frozen in 1.2 ml of sterile 90% FBS+10% DMSO. 
Approximately one week prior to experiment, OP9-DL1 or OP9-GFP cells were 
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thawed from liquid nitrogen and grown in OP9 complete media, expanding to 
additional culture flasks (Corning) as needed to maintain sufficient growth space 
and confluency. Three days prior to establishment of co-culture, OP9-DL1 or 
OP9-GFP cells were plated into either 24-well or 96-well tissue culture treated 
plates (Corning) and allowed to grow to approximately 80% confluency, in a 
humidified 37oC incubator maintained with 5% CO2. Prior to introduction of LSK 
cells, OP9 medium was added to the wells, supplemented with 5ng/ml Flt3L 
(PeproTech, Rocky Hill, NJ) and 5ng/ml Interleukin-7 (PeproTech). Sorted LSK 
cells were maintained in co-culture system for up to 15 days with media 
replacement (complete OP9 medium, supplemented with 5ng/mL Flt3L and 
5ng/mL Interleukin-7) occurring every three days of co-culture.  
For initial measurement of lymphocyte differentiation, 4000 LSK cells were 
plated in each well of a Costar 24 well cell culture plate (Corning) on day 0 and 
were harvested from triplicate wells every other day starting on day 5 and ending 
on day 15, diluting and expanding into new 80% confluent OP9-adherent wells 
when counts exceeded 1 x 106 cells per well.  
For limiting dilution analyses, OP9 stromal cells were treated with 5µg/mL 
Mitomycin C (Acros Organics, Thermo-Fisher Scientific, Waltham, MA) 4-24 
hours prior to initiation of co-culture. For Mitomycin C treatment, growth media 
was removed from 80% confluent OP9-GFP or OP9-DL1 cells and replaced with 
100 µL of complete OP9 medium with 0.1% Mitomycin C. After 30 minutes of 
incubation at 37oC in darkness, the Mitomycin C/OP9 media was removed and 
cells were washed five times with sterile Phosphate Buffered Solution (PBS) 
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containing 2.5% FBS. On day 0, either 1, 3, 6, 10 or 30 cells were sorted into 
individual wells of a Costar 96 well cell culture plate (Corning). Sorted LSK cells 
were maintained in co-culture system for up to 15 days with media replacement 
(complete OP9 medium, supplemented with 5ng/mL Flt3L and 5ng/ml Interleukin-
7) occurring every three days of co-culture. All wells were harvested and 
analyzed for presence of cell surface markers on day 12 for OP9-DL1 co-cultures 
and day 14 for OP9-GFP co-cultures as described above.  
 
RNA Preparation 
Hematopoietic cells from vehicle or TCDD-treated fetuses were isolated 
and sorted in TRIzol (Life Technologies) from GD 7.5 yolk sac, GD 11.5 AGM, 
and GD 14.5 fetal liver. 1-bromo-3-chloropropane (Sigma-Aldrich) was used to 
separate RNA into the aqueous phase after centrifugation. Resulting pellet was 
re-suspended in molecular-biology grade water. Yield and purity were quantified 
spectrophotometrically on a NanoquantTM plate using OD260/OD280 ratio 
(Tecan) and was either made into cDNA or stored at -80oC. RNA was subjected 
to reverse transcription using Tetro cDNA Synthesis kit (Bioline) using both 
anchored-oligo(dT) 18 priming and random hexamer priming options and was 
stored at -20oC until day of assay. 
 
Real-Time Quantitative Reverse Transcriptase PCR  
Primers were selected using the Universal ProbeLibrary version 2.5 for 
Mouse (Roche) and checked for specificity using Primer-Blast (NCBI). cDNA was 
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used as a template in 20µl reaction consisting of 10µM of forward and reverse 
primers and 10µl SensiFAST SYBR No-ROX (Bioline). Gene names, accession 
numbers, and sequences are provided in Table 5. Relative expression change 
was determined using 2ΔΔCt with standardization to housekeeping genes. 
Samples were run in triplicate for each result on a Roche LightCycler480 system 
(Roche Applied Science, Indianapolis, IN). Cycling conditions were 95oC for 2 
min, followed by 45 cycles of 95oC for 5s, 60oC for 10s, and 72oC for 10s.  
For reference genes B-actin and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), Universal ProbeLibrary Mouse Gene Assays (Roche 
Applied Science, Indianapolis, IN) were used according to the manufacturer’s 
directions.  
Table 5. Gene name, accession number and primer sequence used for 
qRT2PCR 
 
Name Accession 5'->3' Forward 5'->3' Reverse 
    
Cyp1A1 NM_009992.4 ccaagaggaagggcatagg gagcagctctgtggctgac 
Cyp1B1 NM_009994.1 agccaggacaccctttcc gcctgaacatccgggtatc 
 
AHR NM_013464.4 cgggttccctgctcagta ccagaagttcaaagctccaaa 
 
ARNT NM_001037737.2 ccagatttcacgtcactcca ttgggaagaacgagtcttgg 
 
TBP1,2 NM_013684.3 ggcggtttggctaggttt gggttatcttcacacaccatga 
 
SDHA1,3 NM_023281.1  gggaatggtttggaacacag tgcgcacagcatcagatt 
HPRT1,4 NM_013556.2 gtcaacgggggacataaaag caacaatcaagacattctttcca 
1 At least two housekeeping genes were used for each time point. Housekeeping genes were 
selected for each day of development based on an initial analysis demonstrating no effect of 
TCDD. 
2 TBP housekeeping gene used on GD 7.5 
3 SDHA housekeeping gene used on GD 11.5 and 14.5 
4 HPRT housekeeping gene used on GD 7.5 and maternal liver 
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Apoptosis of Thymocytes via APO-BRDUTM TUNEL Assay 
Thymocytes were harvested from Notch1ICN-TG mice developmentally 
exposed to vehicle control or 3µg/kg TCDD. One million thymocytes per well 
were incubated overnight in 24 well plates (Corning) at 37oC and 5% CO2 in 
RPMI (Life Technologies) supplemented with 10 mg/mL gentamycin (Gibco, 
Grand Island, NY), 10% FBS (Gibco), and 0.5M 2-Mercaptoethanol (EMD). 
Thymocytes were then stained for surface markers CD4 and CD8 as described 
above. After a 15 minute fixation with 1% paraformaldehyde, thymocytes were 
resuspended in 70% EtOH and frozen at -20o C overnight. A Terminal 
deoxynucleotide transferase dUTP Nick End Labeling (TUNEL) assay was 
performed following manufacturer’s protocol outlined in the Phoenix Flow 
Systems, Inc. APO-BRDUTM Kit (San Diego, CA), eliminating the addition of 
Propidium Iodide/RNase A Solution. Cells were analyzed on BD FACSAria III as 
described above, using FSC-Area by SSC-Area for doublet exclusion, followed 
by identification of thymocytes by presence of both CD4 and CD8. Anti-BrdU 
cells were identified within the thymocyte population by FITC fluorescence. 
 
Statistical Analysis 
Statistical significance was determined and is denoted on graphs and 
tables as a single asterisk for p≤0.05, two asterisks for p≤0.01 or three asterisks 
for p≤0.001.  
For precursor frequency calculations, we first determined an acceptable 
threshold value for a positive response using wild type (C57BL/6) mice. The 
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percentage of CD4+CD8+ cells for each well (Fig. 11A) was used to discriminate 
responsive from non-responsive wells. Using the extreme limiting dilution 
analysis (ELDA) program (Hu and Smyth, 2009), T cell precursor frequencies 
were calculated for CD4+CD8+ percentages at every point from 0.1% to 5.0% of 
the total cell population. The ELDA program returns a Chi Square value for each 
vehicle/TCDD frequency comparison. Chi Square values were plotted at each 
percentage point against the matching cell population percentage (Fig. 11B). The 
peak of this graph, where the Chi Square value indicated the greatest difference 
between control and exposed wells, was determined to be a range including the 
three highest peaks (2.0-2.8). The highest peak value was chosen (2.8%) and 
used to determine progenitor frequency for both B and T lymphocyte precursors. 
Data for the limiting dilution was analyzed and graphed according to the “limdil” 
function contained in the “statmod” package in Rstudio (RStudio, 2012). Our 
calculations are based on a compilation of all data from three replications of the 
OP9-DL1 co-culture system and three of the OP9-GFP co-culture system.  
 
 
 
A. B. 
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Figure 11. Positive growth score cut-off value was determined by graphing Chi 
Square values.  
A. The percent of DP (CD8+CD4+) cells were graphed against B. Chi Square values. 
The highest peaks represent the appropriate range for labeling a positive result. Positive 
counts were made per well and associated Chi Square values calculated by Hu, et al’s 
ELDA software. Images show CD8+CD4+ quadrant (T cells), but similar methods were 
employed for CD19+B220+ (B cells). Figure originally included as supplementary for 
Chapter 3 publication. 
 
For limiting dilution analyses using AHR transgenic mice, data sets were 
cleaned prior to combination for final analysis. Because our yield of LSK cells 
from KO fetuses was occasionally very low, we eliminated repeats that had fewer 
than 20 wells of 30 cells per well. We then compared the remaining experiments 
to the 95% confidence interval previously determined for TCDD-exposed 
C57BL/6 mice (Ahrenhoerster et al., 2014). We eliminated any ELDA 
experiments for which progenitor frequency exceeded 1 in 49.9, using that 
number as indication that insufficient growth was achieved in the co-culture 
system for unclear reasons.  
Graphpad Prism (Graphpad Software, LaJolla, CA) was utilized for 
analysis of variance with Dunnett’s t post-hoc tests, Log-rank (Mantel-Cox) test of 
survival curve comparison, and graphical presentation of all other data.  
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ABSTRACT 
 
The process of hematopoiesis, characterized by long-term self-renewal 
and multi-potent lineage differentiation, has been shown to be regulated in part 
by the ligand-activated transcription factor known as the aryl hydrocarbon 
receptor (AHR). 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a ubiquitous 
contaminant and the most potent AHR agonist, also modulates regulation of adult 
hematopoietic stem and progenitor cell (HSC/HPC) homeostasis. However, the 
effect of developmental TCDD exposure on early life hematopoiesis has not been 
fully explored. Given the inhibitory effects of TCDD on hematopoiesis and 
lymphocyte development, we hypothesized that in utero exposure to TCDD 
would alter the functional capacity of fetal HSC/HPCs to complete lymphocyte 
differentiation. To test this hypothesis, we employed a co-culture system 
designed to facilitate the maturation of progenitor cells to either B or T 
lymphocytes. Furthermore, we utilized an innovative limiting dilution assay to 
precisely quantify differences in lymphocyte differentiation between HSC/HPCs 
obtained from fetuses of dams exposed to 3µg/kg TCDD or control. We found 
that the AHR is transcribed in yolk sac hematopoietic cells and is transcriptionally 
active as early as gestational day (GD) 7.5. Furthermore, the number of 
HSC/HPCs present in the fetal liver on GD 14.5 was significantly increased in 
fetuses whose mothers were exposed to TCDD throughout pregnancy. Despite 
this increase in HSC/HPC cell number, B and T lymphocyte differentiation is 
decreased by approximately 2.5 fold. These findings demonstrate that 
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inappropriate developmental AHR activation in HSC/HPCs adversely impacts 
lymphocyte differentiation and may have consequences for lymphocyte 
development in the bone marrow and thymus later in life.  
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INTRODUCTION 
Hematological malignancies are the fifth most common cancer in the world 
and include lymphomas, acute lymphoblastic leukemias, and myeloproliferative 
neoplasms (Rodriguez-Abreu et al., 2007). These malignancies are the most 
common childhood cancer and the incidence rate for both children and adults 
has increased during the last 40 years (Howlader et al., 2013). One risk factor 
identified for leukemia comes from epidemiological analysis of Vietnam War 
military veterans exposed to the defoliant Agent Orange that was contaminated 
with 2,3,7,8 Tetrachlorodibenzo-p-dioxin (TCDD) (Institute of Medicine, 2011). In 
present day China, children living near electronic waste recycling facilities 
experience daily exposure to a spectrum of dioxin congeners (Han et al., 2011; 
Leung et al., 2011; Shen et al., 2010). Moreover, humans in industrialized 
countries can be exposed to dioxins through daily intake of meat, dairy and 
seafood (Kvalem et al., 2012; Liem et al., 2000). Thus, dioxin exposure continues 
to represent a significant global public health issue with potentially greater 
adverse effects for populations exposed during development because the effects 
can be longer lasting and may occur at lower developmental doses (Dietert et al., 
2010; Hogaboam et al., 2007). 
TCDD is the most potent agonist of the Aryl hydrocarbon receptor (AHR) 
and is known to impact a spectrum of adverse health conditions including 
malignancy, neurological disorders, and immune suppression (Institute of 
Medicine, 2011). We and others have shown that exposure to TCDD leads to 
thymic atrophy and impairs T lymphocyte development (Laiosa et al., 2003, 
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2002). Recently, the AHR has been implicated in mechanisms required for 
maintenance and differentiation of adult hematopoietic stem cells (Boitano et al., 
2010; Casado et al., 2010; Gasiewicz et al., 2010; Lindsey and Papoutsakis, 
2012; Smith et al., 2013). However, AHR-dependent effects on fetal 
hematopoiesis have received little recent attention despite the possibility that 
exposure to AHR agonists early in life could lead to long-term defects of 
hematopoietic stem cell self-renewal or differentiation. 
Hematopoiesis is the process by which immature hematopoietic stem and 
progenitor cells (HSC/HPCs) develop into mature blood and immune cells, and 
during development this process is initiated in the yolk sac (Orkin and Zon, 2008; 
Samokhvalov et al., 2007). In fetal mice, the anatomical location and timing of 
hematopoiesis proceed such that the site of hematopoiesis migrates from the 
yolk sac to the aorta-gonads-mesonephros (gestational day (GD) 8-9), followed 
by the fetal liver and spleen (GD11-GD16). Ultimately HSC/HPCs localize to the 
bone marrow, which remains the site of hematopoiesis throughout adulthood 
(Orkin and Zon, 2008; Robin, C et al., 2003). In response to micro-environmental 
signals in the stem cell niche, a proportion of the long-term HSCs begin 
differentiation along multiple blood cell lineages, and become committed to more 
specific effector cell fates (Luc et al., 2008). For example, progenitors referred to 
as common lymphoid precursors that receive a signal through the trans-
membrane protein Notch1, further differentiate into T lymphocytes whereas B 
lymphocytes are generated from common lymphoid precursors that fail to engage 
Notch1 (Deftos et al., 2000; Zúñiga-Pflücker and Schmitt, 2005). 
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There is a growing recognition that factors that disrupt the processes of 
HSC self-renewal or multipotent lineage differentiation into immune effector cells 
can have profound effects on long-term immunity (Seita and Weissman, 2010). 
For example, mice developmentally exposed to TCDD display persistent immune 
defects indicative of later-life autoimmune disorder (Mustafa et al., 2008) and an 
inability to mount an effective immune response to viral insult (Head and 
Lawrence, 2009; B A Vorderstrasse et al., 2004). Moreover, mice exposed during 
the perinatal period to TCDD exhibit longer-lasting effects than adult-exposed 
mice (Hogaboam et al., 2007). 
While there is considerable evidence connecting adult TCDD exposure to 
immune suppression, the target hematopoietic cell population and the 
mechanism by which immune suppression after developmental exposure is 
occurring have not yet been fully elucidated. Therefore, we set out to test the 
hypothesis that developmental aryl hydrocarbon receptor activation by TCDD 
modulates the capacity of hematopoietic stem cells to undergo lymphocyte 
differentiation. In order to test this hypothesis, we co-cultured fetal liver 
HSC/HPCs in an in vitro co-culture system designed to drive differentiation along 
either the B or the T lymphocyte lineage. Our method of determining B or T 
lymphocyte differentiation capacity is particularly innovative because we have 
created an assay that is a hybrid of stem cell limiting dilution analysis and 
traditional toxicological assay. Importantly, we can accomplish this while 
approaching environmentally-relevant levels of TCDD exposure in utero. Using 
this quantitative in vitro co-culture system, we found a significant decrease in the 
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lymphocyte differentiation potential of HSC/HPCs developmentally exposed to 
TCDD. This decrease in the ability of fetal HSC/HPC to complete normal 
hematopoietic differentiation may increase risk for later-life hematological 
diseases such as malignancies or stem cell exhaustion (Lento et al., 2013; Stein 
and Baldwin, 2013).  
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RESULTS 
 
Developmental exposure to TCDD increases the number of hematopoietic 
progenitor cells in the fetal liver.  
Hematopoietic progenitor cells cultured in the presence of both agonist 
and antagonistic AHR modulators lead to progenitor cell expansion in vitro and 
these new selective AHR modulators hold promise for improved clinical stem cell 
therapies and approaches (Boitano et al., 2010; Smith et al., 2013). However, in 
vivo comparisons with the in vitro data are complicated by differences in dose of 
the modulators, metabolism of the modulator, and presence of additional intrinsic 
and extrinsic factors present in the hematopoietic stem cell niche that could 
modulate progenitor cell differentiation and self-renewal. Thus, as a first step to 
determine the effect of persistent developmental AHR activation on 
hematopoiesis, we tested the effects of transplacental exposure to the non-
metabolizable AHR agonist TCDD on fetal liver HSC homeostasis. Specifically, 
to determine if developmental TCDD exposure affects fetal HSCs, we used flow 
cytometry to examine GD14.5 fetal liver cells from mice developmentally 
exposed to either 3µg/kg TCDD or vehicle control administered to the pregnant 
dam by gavage on GD 0.5 and 7.5. The percentage of HSC/HPC cells defined by 
the absence of lineage markers and expression of Sca-1 and cKit (referred to as 
LSK) is more than two-fold higher in the fetal livers of mice developmentally 
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exposed to TCDD (Fig. 12). Furthermore, the absolute number of LSK cells per 
fetus and the mean fluorescence intensity of Sca-1 containing cells is also 
significantly increased in fetal livers of mice exposed to TCDD transplacentally 
(Fig. 12C & 12D; p≤0.01).  
 
 
Figure 12. Hematopoietic progenitor cell frequency and number increase following 
developmental TCDD exposure in vivo. Pregnant C57BL/6 dams were exposed to 
3µg/Kg TCDD or vehicle control throughout gestation and fetal liver cells were isolated 
on GD 14.5. A) representative fetal liver c-Kit versus Sca-1 flow cytometry plots are 
shown from vehicle- and TCDD-exposed dams. The numbers in each quadrant 
represent the percentage of Lin- cells expressing cKit, Sca-1 or both. B) The percentage 
of fetal liver LSK cells from vehicle- and TCDD-exposed dams are shown. C) The 
percentage of LSK cells was multiplied by total fetal liver cell number to determine 
absolute number of LSK cells. D) The mean fluorescence intensity of Sca-1+ cells. Open 
histograms represent vehicle and shaded histograms represent TCDD. Data are 
presented as the mean + SEM (vehicle n=9; TCDD n=10). Statistical differences were 
determined by ANOVA and Dunnet’s t post-hoc test. An *** is used to denote statistical 
significance with p≤0.001. 
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The AHR is expressed and is transcriptionally active in fetal hematopoietic cells. 
 Alterations in the proportion of fetal HSC/HPC cells following TCDD 
exposure is predicted to be due to AHR expression and transcriptional activation 
in hematopoietic cells. Thus, gene expression of the AHR and its hetero-
dimerization partner ARNT were analyzed in hematopoietic cells obtained from 
yolk sac on GD 7.5, the aorta-gonads-mesonephros (AGM) on GD 11.5 or GD 
14.5 fetal liver during early fetal development. The AHR was expressed at all 
three time points and its gene expression was significantly increased in TCDD-
exposed fetuses relative to control fetuses on GD 11.5 (Fig. 13A; p<0.01). In 
comparison, ARNT was relatively unchanged except in the maternal liver where 
its expression was down modulated following 14.5 days of exposure (Fig. 13B). 
Maternal liver was used as a control to demonstrate the dose and method of 
TCDD-exposure (gavage) was sufficient to activate the adult AHR throughout the 
14.5 day exposure window. Furthermore, induction of Cyp1A1 by TCDD 
exposure in GD 11.5 AGM HSC/HPC cells suggests the AHR-ARNT heterodimer 
is transcriptionally active in the fetus (Fig. 13C). Taken together, these data 
demonstrate the potential of the ligand-activated AHR to impact hematopoiesis in 
the fetus through transcriptional changes in gene expression. 
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Figure 13. AHR and ARNT are expressed in fetal HSC/HPC cells and are 
transcriptionally active. Pregnant C57BL/6 dams were exposed to 3µg/Kg TCDD or 
vehicle control throughout gestation and HSC/HPC cells were sorted and RNA obtained 
from the maternal liver or fetal yolk sac on GD 7.5, aorta-gonadal-mesonephros on GD 
11.5 and fetal liver on GD 14.5. RNA was reverse-transcribed and cDNA PCR amplified 
by quantitative real-time PCR. A) The TCDD-induced fold change of AHR gene 
expression is shown for the three gestational time points and in maternal liver. The 
housekeeping genes used for each developmental time point are indicated in Table 1. B) 
TCDD-induced fold change for ARNT. C and D) The TCDD-induced fold change for 
AHR-ARNT target genes Cyp1A1 and Cyp1B1. The black dot represents the average 
fold change from two independent experiments with the error bars indicating the fold-
change from each individual experiment. RNA was pooled from HSC/HPCs sorted from 
an entire litter.  
 
LSK cells obtained from GD 14.5 fetal livers exposed to TCDD have normal 
growth potential in vitro 
In order to determine if the increase in the LSK cell population in TCDD-
exposed mice was attributed to differences in their proliferative potential, LSK 
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cells were sorted and cultured in vitro using serum free media optimized for 
expansion of short-term self-renewing HSCs and HPCs. To obtain a pure 
population of LSK cells, fetal livers from GD 14.5 mice were dissected and 
mature CD24+ cells were depleted by J11d mediated complement dependent 
lysis as previously described (Schmitt and Zúñiga-Pflücker, 2002). Subsequently, 
cells were prepared for fluorescence activated cell sorting and isolated with 
greater than 95% purity (Fig. 14A & 14B).  
Once placed in culture, LSK cells were supplemented with the stem cell 
growth factor (SCF), where there is an approximately 1000 fold expansion of LSK 
cells over the course of a two-week culture period (data not shown). During the 
initial phase of the culture period, there appeared to be a slight increase in the 
proportion of LSK cells in the culture but this was not statistically significant (Fig. 
14C-14D). Moreover, by the end of the culture, there were no differences 
between the frequency and number of LSK cells obtained from vehicle or TCDD 
exposed fetuses (Fig. 14C-14D). These data indicate that the process of short-
term self-renewal that is facilitated by this in vitro culture system is not a primary 
target of in utero TCDD exposure. 
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Figure 14. LSK cells obtained from GD 14.5 fetal livers exposed to TCDD have 
normal growth potential in vitro. LSK cells were sorted on the FACS Aria III following 
J11d mediated complement-dependent lysis. A) The gating strategy for sorting is shown 
and results from a pre- and post-sort representative sample are displayed. Briefly, viable 
cells based on Sytox blue dead cell exclusion were first gated, followed by doublet 
discrimination using Forward and Side scatter (FSC, SSC) height by width gating. 
Fluorescence gating strategy is shown with top panels showing lineage staining versus 
SSC-area. B) c-Kit+Sca-1+ events were sorted using the FACS Diva version 6.0 
software purity mask. This sorting strategy was employed and purity was determined 
(>95%; data not shown) for all subsequent experiments. After cell sorting, five hundred 
LSK cells were grown in StemSpan SFEM media + 100 ng/ml SCF and cultured for 15 
days. C) Representative histograms of lineage stained cells (CD11b, Ter-119, Gr-1, 
B220, CD3) are shown for days 3, 6 and 9. LSK cells from Vehicle-exposed dams are 
shown with a black line, and LSK cells from TCDD-exposed dams are illustrated in gray. 
D) cKit versus Sca-1 expression in LSK growth cultures is shown for Vehicle (left hand 
contour plots) or TCDD (right hand contour plots). The numbers in each quadrant 
represent the percentage of viable Lin- cells. Experiment was repeated three times. 
 
 
TCDD induces cell cycle arrest in in vitro generated thymocytes 
We have previously demonstrated that thymocytes obtained from adult 
mice exposed to TCDD undergo cell cycle arrest within hours of exposure 
(Laiosa et al., 2003), and that this effect is due to activation of the AHR in the 
hematopoietic cell population directly (Staples et al., 1998). Given the importance 
of AHR signaling in HSCs (Boitano et al., 2010; Gasiewicz et al., 2010), and 
thymic atrophy, a critical question that remains is what effect TCDD exposure 
has on HSC differentiation into cells of the lymphoid lineage. Up until now, 
answering this question has proven difficult because of the different anatomical 
locations where hematopoiesis and thymopoiesis occur. However, by using the 
OP9-DL1 in vitro system of thymocyte differentiation (Schmitt and Zúñiga-
Pflücker, 2002), we can track the transition of hematopoietic stem and progenitor 
cells into thymocytes and determine the effect of AHR activation on this process. 
The first step in this process was to determine if OP9-DL1 in vitro generated 
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thymocytes have TCDD sensitivity similar to that of thymocytes obtained in vivo. 
This was accomplished by sorting unexposed LSK cells harvested from murine 
fetal livers into OP9-DL1 co-cultures and maintaining cells for 12 days. On day 
11, co-cultures were exposed to various concentrations of TCDD or DMSO 
vehicle control. Twelve hours after exposure, BrdU incorporation within each 
stage of thymocyte development was analyzed. We observed an equivalent 
percentage and number of cells expressing CD44 and CD25 twelve hours after in 
vitro TCDD exposure indicating the distribution of early thymocyte progenitor 
populations within the co-cultures are unaffected by this short exposure (Fig. 
15A). However, BrdU incorporation is significantly attenuated in the CD44-CD25+ 
(DN3) population of thymocyte progenitors (Fig. 15B; p≤0.05). Moreover, 
significant reduction in BrdU incorporation can be detected in cultures exposed to 
as low as 0.001nM TCDD (Fig. 15C; p≤0.05). Importantly, the nearly 50% 
reduction in BrdU within the CD44-CD25+ and CD44-CD25- populations is highly 
correlated with the TCDD-induced cell cycle inhibition observed in these specific 
thymocyte progenitor populations in vivo (Laiosa et al., 2003).  
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Figure 15. BrdU incorporation is decreased in TCDD-exposed thymocyte 
progenitors derived from LSK cells grown in OP9-DL1 co-cultures. A) 
Representative CD25 versus CD44 flow cytometry plots for day 12 OP9-DL1 co-cultures 
exposed in vitro to vehicle or 1nM TCDD for 24 h. Numbers inside each quadrant 
  
 
72 
represent the percentage of CD4-CD8- (DN) cells. B) Intracellular BrdU incorporation 
was measured in each thymocyte progenitor population and representative BrdU 
histograms are shown for the CD44-CD25+ population from one vehicle and one 1nM 
TCDD exposed culture. C) The percent of BrdU+ cells for each population of thymocyte 
progenitors 12 h after in vitro exposure to TCDD or vehicle. Cultures were dosed on day 
11, and surface staining and intracellular BrdU staining was conducted on day 12. 
Experiment was repeated two times. Data are presented as the mean + SEM with 6 
wells analyzed per group. Statistical differences are determined by ANOVA and 
Dunnet’s t post-hoc test. An * is used to denote statistical significance with p≤0.05.  
 
 
Kinetics of DL1-mediated thymocyte differentiation are equivalent in control and 
developmental TCDD-exposed HSCs 
The demonstration that in vitro TCDD exposure in the OP9-DL1 – LSK co-
culture system models the in vivo response to TCDD suggested that this system 
could be employed to follow the lymphocyte differentiation potential of LSK cells 
exposed to TCDD in utero. Thus, pregnant dams were exposed to vehicle or 
3µg/Kg TCDD on GD 0.5 and 7.5 followed by cell sorting of LSK hematopoietic 
stem and progenitor cells on GD 14.5. LSKs were then placed into OP9-DL1 or 
OP9-GFP control co-cultures and thymocyte or B lymphocyte differentiation was 
tracked every two days in cultures seeded with either vehicle or TCDD-exposed 
LSK cells. Following developmental exposure to TCDD, no statistically significant 
difference was found in the rate of LSK maturation into thymocytes in OP9-DL1 
co-culture when 4000 cells were plated per well (Fig. 16). Similar results were 
found with B cell progenitors grown in co-culture with OP9-GFP cells (Fig. 17). 
Notably, a slight but not statistically significant difference in the frequency of 
CD4+CD8+ thymocytes produced by OP9-DL1 co-cultures was detectable 
between the vehicle- and TCDD-exposed wells at the end of the culture period. 
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This slight difference led us to conclude that any subtle variation may have been 
obscured by the high number (4000) of starting LSK cells per well. 
 
Figure 16: Fetal liver LSK cells co-cultured with OP9-DL1 bone marrow stromal 
cells undergo thymocyte differentiation with similar kinetics following 
developmental vehicle or TCDD exposure. Fetal liver LSK cells were isolated on 
GD14.5 as described and placed into OP9-DL1 co-cultures. Beginning on day 6 of co-
culture, and continuing every other day, cells were harvested, counted, and stained with 
fluorochrome-labeled antibodies directed against CD4, CD8, CD44, and CD25. A) 
Representative CD4-CD8- gated cells were analyzed for the percentage of CD44 versus 
CD25 from vehicle- and TCDD-exposed dams. The numbers in each quadrant represent 
the percentage of viable cells within the CD4-CD8- gate. B) CD8 versus CD4 expression 
on each day of the differentiation assay is shown. The numbers in each quadrant 
represent the percentage of viable cells. Experiment was repeated five times. 
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Figure 17: Fetal liver LSK cells co-cultured with OP9-GFP bone marrow stromal 
cells undergo B lymphocyte differentiation with similar kinetics following 
developmental vehicle or TCDD exposure. Fetal liver LSK cells were isolated on 
GD14.5 as described and placed into OP9-GFP co-cultures. Beginning on day 6 of co-
culture, and continuing every other day, cells were harvested, counted, and stained with 
fluorochrome-labeled antibodies directed against CD4 and CD8, and B220. 
Representative flow cytometry plots were analyzed for the percentage of B220 versus 
CD4 and CD8 from vehicle- and TCDD-exposed dams. The numbers in the bottom right 
quadrants represent the percentage of viable B lymphocytes. Experiment was repeated 
five times. Figure originally included as supplementary. 
 
 
 
Developmental TCDD exposure decreases lymphocyte differentiation potential of  
 
LSK cells  
In order to precisely quantify the lymphocyte differentiation potential on a 
per cell basis following developmental vehicle- or TCDD-exposure, a limiting 
dilution approach was employed to the OP9 – LSK co-culture system. Following 
prenatal TCDD exposure, exactly 1, 3, 6, 10, or 30 LSKs from GD 14.5 fetuses 
were deposited by FACS into individual wells in 96 well plates containing OP9-
DL1 or OP9-GFP stromal cells. On day 12 for the OP9-DL1 co-cultures, cells 
from individual wells were harvested and stained with the thymocyte surface 
  
 
75 
markers CD4 and CD8 and the percentage of wells containing CD4+CD8+ cells 
was recorded. We found 1 in 16.9 (95% CI: 14.2-20.2) LSK cells have T cell 
potential compared with nearly 1 in 39.6 LSK (95% CI: 31.5-49.9) cells 
possessing T cell potential from the developmentally TCDD-exposed fetuses 
(Fig. 18A; Table 6; p<0.01). Developmental TCDD exposure was observed to 
also reduce by nearly two-fold the B lymphocyte precursor frequency for LSK 
cells as determined by day 14 OP9-GFP limiting dilution co-culture analysis (Fig. 
18B; Table 7). Taken together, these data demonstrate that prenatal TCDD 
exposure significantly decreases the number of fetal liver LSK cells with potential 
to produce T and B lymphocyte progeny. 
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Figure 18: Developmental TCDD exposure decreases lymphocyte differentiation 
potential of murine fetal liver HSCs. Fetal liver LSK cells were isolated on GD14.5 as 
described. Exactly 1 to 30 LSK cells were directly sorted into individual wells of a 96 well 
culture plate containing a confluent layer of mitomycin C-treated OP9-DL1 or OP9-GFP 
cells and maintained for 12 (DL1) or 14 (GFP) days. Individual wells were analyzed for 
the generation of thymocytes (CD4+CD8+) or B cells (CD19+B220+). The number of 
positive responses for each cell concentration was entered into the limdil package in R 
Studio (RStudio, 2012) and plotted using ELDA software. A) Thymocyte wells from OP9-
DL1 co-cultures were scored as a positive response if ≥2.8% of total cells in the well 
were CD4+CD8+. B) B-lymphocyte wells from OP9-GFP co-cultures were scored as a 
positive response if ≥2.8% of total cells in the well were CD19+B220+. Precursor 
frequency is reported in Tables 2 and 3. Vehicle samples are represented by red circles 
(3 replicates) and TCDD-exposed samples are represented by blue filled circles (3 
replicates). 95% CI is shaded around each treatment (vehicle-pink; TCDD-light blue; 
p≤0.001). 
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Table 6. Thymocyte progenitor frequencies after developmental exposurea  
______________________________________________________________________________________________________________ 
   Progenitor frequency (95% CI)   p-value  
______________________________________________________________________________________________________________ 
Thymocyte vehicle  1 in 16.9 (14.2-20.2)b,c      
Thymocyte TCDD   1 in 39.6 (31.5-49.9)b,c   ≤0.001 
______________________________________________________________________ 
aPregnant C57BL/6J mice were exposed on gestational days (GD) 0.5 and 7.5 to either 3µg/Kg of 
TCDD or vehicle; fetal liver LSK cells were isolated on GD 14.5 as described. 
bProgenitor frequencies were calculated using the limdil package in R-Studio after 12 days of co-
culture with OP9-DL1 cells and as described in Fig. 5 legend. 
cEach limiting dilution was repeated three times and the total number of wells for each cell 
concentration from all three experiments was pooled for the limdil analysis. 
 
 
Table 7. B lymphocyte progenitor frequencies after developmental 
exposurea 
______________________________________________________________________________________________________________ 
     Progenitor frequency (95% CI)  p-value  
______________________________________________________________________________________________________________ 
B lymphocyte vehicle  1 in 28.0 (21.6-36.2)b,c      
B lymphocyte TCDD  1 in 62.3 (44.0-88.2)b,c   ≤0.001 
aPregnant C57BL/6J mice were exposed on gestational days (GD) 0.5 and 7.5 to either 3µg/Kg of 
TCDD or vehicle; fetal liver LSK cells were isolated on GD 14.5 as described. 
bProgenitor frequencies were calculated using the limdil package in R-Studio after 14 days of co-
culture with OP9-GFP cells and as described in Fig. 5 legend. 
cEach limiting dilution was repeated three times and the total number of wells for each cell 
concentration from all three experiments was pooled for the limdil analysis. 
  
  
 
78 
 
DISCUSSION 
In the present study, we demonstrate that prenatal exposure to TCDD 
causes alterations in fetal HSC/HPC homeostasis and lymphocyte differentiation. 
As shown in a novel co-culture limiting dilution assay, the ability of HSC/HPCs to 
differentiate into T lymphocytes is decreased nearly two and a half fold following 
developmental exposure to environmentally-relevant levels of the AHR agonist 
TCDD. This decrease in T lymphocyte differentiation ability occurs despite an 
increase in the overall number of fetal liver HSCs on GD14.5. The consequences 
of in utero activation of the AHR on HSC/HPC cell differentiation may provide 
insight into a spectrum of later life blood disorders ranging from stem cell 
exhaustion to leukemia (Seita and Weissman, 2010).  
The observed increase in fetal LSK cells is consistent with studies 
showing similar alterations in adult bone marrow, however, the in vitro co-culture 
functional assay offers advantages compared with more traditional 
immunotoxicological hematopoiesis assays. Previous research has used stem 
cell transfer to determine the eventual differentiation ability of TCDD-exposed 
cells (Casado et al., 2011; Fine et al., 1989). However, these methods use an 
abundance of stem cells isolated from fetal livers and/or bone marrow. For 
example, when seeding in vitro OP9 cultures with 4000 LSK cells a sufficient 
number of LSK cells possessing T or B lymphocyte potential were present 
impacting the sensitivity necessary for determining if in utero exposure to TCDD 
impairs differentiation. It is possible that earlier LSK transfer experiments may 
have the same effect. To overcome the obstacle an excess of cells in an assay 
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may present, limiting dilution is used to determine frequencies of cells in a mixed 
population that have a particular function and therefore is commonly used for 
progenitor cell applications. The benefit of the in vitro limiting dilution co-culture 
differentiation system that we use is the ability to track the progression of a single 
HSC to its eventual progeny. Furthermore, numerous single cells from one 
sample of sorted HSCs can be tested to determine a numerical differentiation 
potential. This method allows focus not only on individual effects, but also on the 
earliest steps in differentiation. While the frequency of lymphocyte differentiation 
using the OP9 co-culture system has been determined using limiting dilution 
analysis from hematopoietic precursors in mice (Balciunaite et al., 2005) and in 
humans (De Smedt, Magda et al., 2011; Kyoizumi et al., 2013), this is the first 
time it has been employed to test the effect of a developmental toxicological 
exposure on a progenitor cell population’s ability to differentiate.  
A limitation of the limiting dilution analysis is that cells identified by an 
absence of lineage markers, and the presence of Sca-1 and cKit (LSK cells) 
comprise a heterogeneous population of progenitor cells with a range of long- 
and short-term self-renewal capacity. Thus one interpretation of this research is 
that developmental exposure to TCDD causes a shift in the composition of long- 
to more short-term self-renewing progenitor cells identifiable by the LSK surface 
proteins. For example, LSK cells with long-term self-renewal potential have full 
multi-lineage differentiation potential. In comparison, cells transitioning from long-
term to short-term self-renewal still maintain multi-lineage potential. However, 
their capacity to differentiate into any lineage becomes more restricted as they 
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mature and can be biased away from production of the common lymphoid 
precursors that directly produce lymphoid restricted cells. In support of this 
interpretation, we performed a test of heterogeneity for each limiting dilution 
experiment known as a log-dose slope test. We found that all treatment groups 
produced a log-dose slope of less than 1 (data not shown). A slope less than 1 
demonstrates that the fetal liver LSK populations tested are a heterogeneous cell 
population (Hu and Smyth, 2009), with the TCDD-exposed fetuses producing a 
LSK cell population with significantly more heterogeneity than controls.  
In support of the conclusion that developmental TCDD exposure changes 
the composition of the self-renewal potential of fetal LSKs, we observe higher 
Sca-1 expression on GD 14.5 (Fig. 12). Others have correlated high levels of 
Sca-1 expression with decreased differentiation in the erythroid lineage (Azalea-
Romero et al., 2012) and decreased ability to form myeloid colonies (Bradfute et 
al., 2005) as well as patterns of decreased T cell lymphopoiesis in constitutively-
expressing Sca-1 transgenic mice (Bamezai et al., 1995). Furthermore, in a 
mouse model for the autoimmune disease lupus, up-regulation of Sca-1 
correlated with a more severe disease state (Kumar et al., 2005). Taken 
together, this supports Sca-1 as a potential target identifying loss of multi-lineage 
differentiation due to developmental exposure to TCDD. The higher mean 
fluorescence, and thus protein expression of Sca-1 could predict an increased 
risk of hematopoiesis defects over the life-course. 
In summary, we have for the first time demonstrated that prenatal 
exposure to the environmental toxicant and AHR agonist TCDD significantly 
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increases the number of HSCs, but on a per-cell-basis decreases the ability of 
fetal liver LSK cells to differentiate into B and T lymphocytes. As with in vivo 
experiments, the cell cycle effects of TCDD exposure were shown to be the most 
dramatic in the DN3/DN4 stage of thymocyte differentiation in vitro. We used a 
lymphocyte differentiation assay combined with extreme limiting dilution analysis 
(Hu and Smyth, 2009) to follow prenatally-exposed LSK cells from the progenitor 
stage through to lymphocyte commitment, arriving at a numerical differentiation 
potential. The in vitro co-culture assay allowed us to focus on TCDD’s effect on 
only the LSK cells, without any potential cross-signaling from TCDD-exposed 
supporting tissues. Additionally, the single cell sorting procedure enabled us to 
examine one LSK cell at a time to determine its ability to differentiate into a 
lymphocyte. Utilization of an in vitro co-culture system to test the effects of 
developmental toxicological exposures on hematopoietic stem cells is not only 
novel, but also preferable to some types of in vivo studies due to the fast, concise 
measures of immunological impact. Our approach to determining lymphocyte 
differentiation potential could be modified to test the developmental 
immunotoxicological effects of other compounds. Finally, this approach could 
facilitate analysis of the sensitivity of other tissue-specific stem and progenitor 
cells to developmental exposures.  
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ABSTRACT 
Environmental exposures during gestation can profoundly affect future 
disease development. Immune cells, along with all other blood cells, descend 
from hematopoietic stem cells (HSCs), which are formed in utero. Exposure to 
2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) in utero has previously been shown 
to decrease the potential of fetal liver HSCs to differentiate into mature 
lymphocytes and to shift the balance of adaptive and innate immune response in 
adult offspring. However, it is not known whether these effects are due to fetal or 
maternal factors. We hypothesized that persistent developmental aryl 
hydrocarbon receptor (AHR) activation in the fetal HSCs was responsible for the 
immune dysfunction, as TCDD is a potent AHR agonist. HSCs were harvested 
on GD 14.5 from gene-targeted mutant AHR mice developmentally exposed to  
3 µg/kg TCDD or vehicle control. HSCs were quantified and placed into T 
lymphocyte differentiation cultures using a limiting dilution approach. We found 
the ability for HSCs to differentiate into mature thymocytes is mediated by the 
AHR in the individual fetuses. Specifically, the T cell differentiation potential of 
HSCs from TCDD-exposed fetuses lacking an AHR is similar to that of HSCs 
from vehicle-exposed wild type fetuses. Conversely, the TCDD-exposed siblings 
who had an AHR produced HSCs with a diminished T cell precursor potential. 
These data suggest that developmental AHR activation in HSCs reprograms the 
balance between self-renewal and differentiation, potentially affecting immune 
system development and function later in life.  
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INTRODUCTION 
Hematopoietic stem cells (HSCs) are the foundational cells of the blood 
system, responsible for maintenance of all cells in the blood and immune system 
by balancing the processes of self-renewal and lineage differentiation to produce 
mature effector cells. The process of hematopoiesis maintains these immune 
cells throughout a person’s lifetime. Consequently, there is a growing recognition 
that factors that disrupt the processes of HSC self-renewal or differentiation can 
have profound effects on long-term immunity (Seita and Weissman, 2010; 
Yamada et al., 2013). For example, transplacental exposure to the ubiquitous 
environmental contaminant 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) leads to 
numerous immunological deficits later in life. 
TCDD, which is produced as a combustion by-product, mediates its 
immunotoxicity in adult mice by binding to and activating the aryl hydrocarbon 
receptor (AHR), an important regulator of immune system development and 
function. AHR, a basic helix-loop-helix protein and member of the PAS family of 
transcription factors, is a principle player in the detoxification pathway of many 
environmental contaminants in addition to dioxins such as TCDD, specifically the 
halogenated aromatic hydrocarbons, including polychlorinated biphenyls (PCBs), 
aromatic amines, and polycyclic aromatic hydrocarbons (PAHs). The AHR is 
evolutionarily conserved, and can be activated by either endogenous or 
exogenous ligands (Smith et al., 2013).  
AHR is known to be implicated in regulation of immune processes 
including inflammation (Hanieh, 2014; Nguyen et al., 2013) and autoimmunity 
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(Apetoh et al., 2010; Nguyen et al., 2013). The AHR is essential for immune 
development, including regulating hematopoiesis (Casado et al., 2010) and 
inducing regulatory T cells (N. P. Singh et al., 2011; Wu et al., 2011). However, 
most immunological research using TCDD as an AHR agonist uses adult animals 
or cell culture lines (Beedanagari et al., 2010b; Benson and Shepherd, 2011; 
Casado et al., 2011; Kerkvliet, 2009; Laiosa et al., 2002; Takamura et al., 2010). 
Almost all studies involving developmental TCDD exposures have focused only 
on adult endpoints (Lew et al., 2009; B A Vorderstrasse et al., 2004) and not 
directly on the HSCs. Understanding specifically the mechanisms by which AHR 
activation during development causes immune system malfunction and where it 
impacts hematopoiesis remains a significant knowledge gap.  
 The AHR is found in embryonic stem cells (Ko et al., 2014) and HSCs 
(Singh et al., 2009), and we have found that it is up-regulated in HSCs on 
GD11.5 following developmental exposure to 3µg/kg of TCDD (Ahrenhoerster et 
al., 2014). Our earlier research illustrates that developmental dioxin exposure 
decreases the ability of HSCs to differentiate into B or T lymphocytes 
(Ahrenhoerster et al., 2014). However, whether this is due to AHR activation in 
the fetus, the placenta, or the mother has yet to be elucidated. Therefore we set 
out to determine the mechanism by which the decreased differentiation occurs, 
hypothesizing that the AHR in fetal HSCs is directly affected by exposures during 
gestation.  
 In order to test this hypothesis, we co-cultured fetal liver HSCs, defined as 
Lin-, cKit+, Sca-1+ (LSK) cells, in an in vitro system designed to drive thymocyte 
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differentiation. LSKs were isolated from fetuses of AHR heterozygous (HZ; 
AHR+/-) x AHR knockout (KO; AHR-/-) or HZ x HZ crosses, thus producing 
siblings of different genotypes while holding all other variables related to 
development constant. Using limiting dilution analysis to examine the 
differentiation potential, we found a significant decrease in the thymocyte 
differentiation potential of HSCs developmentally exposed to TCDD and isolated 
from fetuses possessing AHR. HSCs isolated from fetuses from the same mother 
but lacking AHR did not exhibit a decreased differentiation potential. This model 
is especially robust as it allows us to focus on AHR activation in the fetus while 
providing a uniform uterine environment during gestation. These findings support 
the role of AHR in the fetus as a target of TCDD developmental immunotoxicity.  
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RESULTS 
The question of whether AHR gene dosage impacts response has been 
considered by us and other researchers.  Others have shown no response 
difference between AHR+/+ (wild type; WT) or AHR+/- (HZ) mice, as both 
possess the AHR+ allele (K. P. Singh et al., 2011). We similarly found no 
significant difference in co-culture growth potential (unpublished data), so in our 
experiments, we combined AHR+/+ with AHR+/- to represent AHR+ HSCs and 
compared them to AHR- HSCs, consisting entirely of AHR-/- (KO).  
 
HSCs from AHR+ fetuses developmentally-exposed to TCDD showed a 
decreased potential to differentiate into mature thymocytes in comparison to 
HSCs from AHR- fetuses developmentally-exposed to TCDD. 
Developmental exposure to the potent AHR agonist TCDD in C57BL/6 
(WT) mice decreases lymphocyte differentiation potential, and the AHR is 
expressed and transcriptionally active in fetal HSCs (Ahrenhoerster et al., 2014). 
We therefore hypothesized that the differentiation impairment following 
developmental TCDD exposure is due to activation of the AHR in the fetus, thus 
impacting HSCs at a very early timepoint in development.  
Among TCDD-exposed siblings developing in the same uterine 
environment, the HSCs from AHR- fetuses were over two-fold more likely to 
complete differentiation into mature thymocytes than HSCs from their AHR+ 
siblings (Fig 19A & C). This supports the hypothesis that the differentiation-
limiting actions of TCDD are acting through the AHR in fetal HSCs and that the 
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absence of an AHR provides an element of protection to the HSCs exposed to 
TCDD during thymocyte commitment. 
In order to further clarify our initial findings that the AHR must be present 
in order for TCDD to cause decreased differentiation of HSCs, we further 
hypothesized that HSCs isolated from either AHR+ or AHR- fetuses 
developmentally exposed to vehicle control throughout gestation would have 
comparable thymocyte differentiation potential. Using limiting dilution analysis, 
we measured the differentiation potential of HSCs isolated from sibling AHR+ 
and AHR- fetuses developmentally exposed to vehicle control. We found that 
HSCs from vehicle-exposed AHR+ and AHR- fetuses did not differ in thymocyte 
differentiation potential (Fig. 19B & 19C).  
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Figure 19. Presence of fetal AHR decreases lymphocyte differentiation potential of 
murine fetal liver HSCs exposed developmentally to TCDD, while vehicle-exposed 
HSCs show no difference in differentiation potential regardless of AHR presence. 
Fetal liver LSK cells were isolated on GD14.5 as described. Exactly 1 to 30 LSK cells 
were directly sorted into individual wells of a 96 well culture plate containing a confluent 
layer of mitomycin C-treated OP9-DL1 cells and maintained for 12 days. Individual wells 
were analyzed for the generation of thymocytes (CD4+CD8+). The number of positive 
responses for each cell concentration was entered into the limdil package in R Studio 
(RStudio, 2012) and plotted using ELDA software (Hu and Smyth, 2009). Thymocyte 
wells from OP9-DL1 co-cultures were scored as a positive response if ≥2.8% of total 
cells in the well were CD4+CD8+. A) HSCs isolated from fetal mice developmentally 
exposed to 3µg/kg of TCDD throughout gestation (pooled data from 5 separate 
experiments); B) HSCs isolated from fetal mice developmentally exposed to vehicle 
control throughout gestation (pooled data from 3 separate experiments); C) Calculated 
precursor frequency; AHR- samples represented by orange and AHR+ samples 
represented by green; 95% CI is indicated by a color-matched shaded area around each 
treatment.  
 
 
 
A. B. 
C. 
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AHR knock-out fetuses are slightly less likely to survive to parturition. 
 Through the duration of limiting dilution experiments with AHR transgenic 
mice, the number of KO fetuses was anecdotally observed to be smaller than the 
number of either WT or HZ fetuses. We recorded the genotypes of all AHR 
variant fetuses as genotyped during all repeats of this experiment and observed 
genotype ratios were compared to expected genotype ratios using Chi square 
analysis (Table 8). We found that on average there were fewer KO fetuses than 
expected based on predicted Mendelian inheritance ratios, although none of the 
values reached levels of significance at the p≤0.05 value.  
 
Table 8  
Genotype results of offspring from AHR transgenic matings 
1Maternal GT in all cases was HZ 
2p-value calculated by Chi-square analysis, comparing observed to expected genotype ratios 
Paternal GT1 treatment #WT #Het #KO p-value2 
HZ vehicle 40 68 33 0.65 
HZ TCDD 23 28 14 0.15 
KO vehicle - 21 11 0.11 
KO TCDD - 12 8 0.50 
HZ vehicle + TCDD combined 63 96 47 0.18 
KO vehicle + TCDD combined - 33 19 0.07 
 
Litters fathered by AHR KO mice are significantly less likely to survive until 
parturition. 
We observed in the AHR transgenic mice, anecdotally, a high number of 
fetal reabsorptions or spontaneous abortions, determined by masses of tissue in 
the uterus which are significantly smaller than viable fetuses. It was noted that in 
these experiments, a larger percentage of fetal reabsorptions were observed 
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when the father was a KO male than in uteri of exclusively WT x WT vehicle 
mice, reported as 9.69% ± 11.6% in the literature (Kusakabe et al., 2008), and 
similarly observed as 9.12% ± 11.7% in our laboratory (unpublished observation).  
We attempted to genotype the tissue masses that were in the process of 
being reabsorbed, but the placenta is a mixture of fetal and maternal tissue which 
we were unable to separate. Given that all mothers were HZ, all electrophoresis 
gel genotype results showed double bands, representative of the HZ genotype. 
However, the mean number of fetal reabsorptions per litter with a HZ father was 
1.08, while with a KO father, it was 2.56 (p≤0.05). Additionally, while the 
percentage of fetal reabsorptions from a HZ father was not significantly different 
from WT x WT matings (Z-test; p=0.39), it was significantly higher when the 
father was a KO (Table 9; Z-test; p≤0.05). Interestingly, adding the number of 
reabsorbed fetuses to the number of KO fetuses brings the genotype ratio closer 
to the expected 50% with KO father and 25% with HZ father (Tables 8 and 9).  
 
Table 9 
Reabsorbed fetuses (spontaneous abortions) by parental genotype  
Maternal GT Paternal GT # reabsorbed % reabsorbed p-value* 
HZ HZ 19 12.3% 0.20 
HZ KO 22 19.4% 0.01 
WT WT 36 7.6% 0.14 
 
*p-values based on z-test comparing percent reabsorptions to published vehicle WT reabsorption 
percentages (Kusakabe et al., 2008) 
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Genotype does not affect size of maternal and fetal sections of placentae. 
Because we saw an increase in the number of fetal reabsorptions when the 
father was AHR- and because the number of viable fetuses trended toward 
AHR+, we hypothesized that a higher percentage of AHR- fetuses were not 
surviving gestation. Perturbation of cell death or proliferation-related proteins 
might deter the growth and maintenance of the placentae, driving subsequent 
fetal reabsorption. Furthermore, placental development has been used as a 
measure of genetic or epigenetic defect (Susiarjo et al., 2013), potentially 
resulting in a failed placenta followed by fetal death and reabsorption. We 
collected, preserved, and stained placenta samples from each AHR genotype of 
fetuses at GD14.5 and then measured the fetal and maternal regions of the 
placenta using the methods previously described (Susiarjo et al., 2013) (Fig. 20A 
& B). We did not find a significant difference between the various genotypes (Fig. 
20C, p=0.37) at GD14.5. However, in consultation with Dr. Martha Susiarjo 
(Susiarjo, 2014), and also with placental pathologist Dr. Sara Szabo (Szabo, 
2014), we determined that GD14.5 is too late developmentally to witness 
breakdown of the placenta. GD 11.5 or earlier coincides with early placental 
failure and histological identification of abnormality that may lead to fetal death 
and reabsorption. Additionally, one of the most accurate means of determining 
placental insufficiency is by comparing mass of placenta in each experimental 
group--a procedure we had not followed. Our lab’s future developmental work 
with mice will include addition of earlier harvest timepoints and placental weights 
(Fig 21).   
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Figure 20. Labyrinth to placenta area ratio does not differ by genotype on GD14.5. 
Labyrinth is fetal portion of placental, as identified by presence of nucleated red blood 
cells. “Placenta” measurements include both the fetal and maternal portions illustrated in 
A and B. A) Representative section of a placenta harvested on GD14.5 viewed at the 
magnification necessary to differentiate maternal and fetal sections (40x); B) Cross-
section of full placenta, piecing together numerous sections at lower magnification to 
illustrate placement on a full placenta (100x). No actual measurements were made at the 
lower magnification. C) Mean ratio of labyrinth (fetal) to full placenta (fetal + maternal 
regions) (p=0.37; n=3 of each genotype).  
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Figure 21. Mean placental weight differs between mice developmentally exposed 
to TCDD or vehicle control. Data from one sample experiment, illustrating the varied 
masses of placentae harvested on GD11.5 from WT mice developmentally exposed to 
either 3µg/kg TCDD or vehicle control. (n=8 vehicle; n= 22 TCDD; p≤0.01) 
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DISCUSSION 
In the present study, we demonstrate that prenatal exposure to 
environmentally-relevant levels of TCDD acts through the fetal AHR to cause an 
alteration in lymphocyte differentiation ability. We show that a lack of AHR 
provides protection against the effects of developmental TCDD exposure, and 
that HSCs isolated from TCDD-exposed AHR- fetuses are able to complete T 
lymphocyte commitment at a frequency similar to HSCs developmentally 
exposed to vehicle control. After developmental TCDD exposure, HSCs from 
AHR+ mice, gestated in the same maternal environment as AHR- mice, exhibited 
a roughly two-fold decreased ability to commit as T lymphocytes, thus supporting 
the role of the fetal AHR in lymphocyte differentiation.  
While our original hypothesis was supported, we are less than fully 
confident in our results, due to several inconsistencies in the data. AHR KO mice 
have deficiencies in multiple systems (Fernandez-Salguero et al., 1997). Given 
that the AHR is located in almost all murine and human tissues, additional, 
additional non-hematological defects likely exist, which might explain our 
difficulties in achieving consistent results throughout our experimental repeats.  
In our experiments, we crossed HZ dams with either HZ or KO males, 
resulting in both AHR+ (HZ and WT) and AHR- (KO) fetuses housed in AHR+ 
mothers, to decrease external effects and to enable us to focus on fetal effects 
alone, controlling for any potential maternal factors that might alter development 
and/or hematopoiesis. We relied heavily on male AHR KO mice in order to 
increase the likelihood of KO fetuses and provide greater power to our HSC 
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differentiation calculations. HZ x HZ crosses have published 1:2:1 ratios of 
WT:HZ:KO (Schmidt et al., 1996), but the AHR has recently been implicated for 
its role in embryonic development (Ko et al., 2014; Sartor et al., 2009). While 
research shows that activation of the AHR can cause defects in development, 
absence of the AHR might also affect development. The lower number of AHR- 
fetuses found on GD14.5 supports the likelihood that AHR KO males have 
multiple defects, including reproductive ones. AHR KO males do display defects 
in seminiferous tubule and sperm development and are less likely to fertilize eggs 
(D. A. Hansen et al., 2013). It is therefore possible that fewer eggs were 
successfully fertilized or that those which were fertilized had genetic defects that 
resulted in spontaneous abortion. In fact, our counts of fetus size support this, in 
that AHR litters are slightly smaller than C57BL/6 litters, though not at a 
statistically significant level (data not shown). The HZ mothers were able to carry 
litters to term, so the defect does not seem to be entirely dependent on them and 
any maternal effect would be constant throughout these experiments, regardless 
of paternal genotype. We are not the first to notice the variations in genotype 
ratio (Hirabayashi and Inoue, 2009), although others posit that the lower KO 
ratios are due to competitive fertilization by AHR+ sperm instead of the demise of 
KO fetuses.   
In order to reach sufficient power in our limiting dilution experiments, the 
results from several experiments were combined, and in all but one case, we 
examined only vehicle-exposed or only TCDD-exposed cohorts on any given 
day. The TCDD-exposed cohorts each gave very similar results with little 
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variation. However, we completed over twice as many vehicle-exposed 
experiments in order to establish consistent repeats. As described in the 
“Materials and Methods” section, we eliminated experiments with insufficient 
HSC co-culture growth, as defined by a calculated differentiation potential in 
excess of the published 95% confidence interval for WT TCDD-exposed HSCs 
(Ahrenhoerster et al., 2014). We further eliminated experiments lacking sufficient 
harvest of LSKs to sort a minimum of twenty 30-count wells. Additionally, the 
data points for the vehicle-exposed mice, while overall consistent, did not fit the 
graph constructed by the ELDA program as tightly (Fig. 19B) as did the points on 
the TCDD-exposed graph (Fig. 19A). 
It is possible that we saw less variation in experiments with the TCDD-
exposed cohorts because the presence of the potent AHR agonist TCDD is a 
stronger decision-maker in terms of lineage commitment than other endogenous 
mechanisms. Therefore, without the presence of this strong AHR agonist, the 
whole-organism defects of the AHR KO model become the predominant lineage 
decision-maker. Our work with this particular whole-mouse AHR KO model has 
posed several new questions about determination of AHR’s effect on 
hematopoiesis in the fetus. 
One possibility, recently illuminated by the NIH Revitalization Act (Clayton 
and Collins, 2014), is related to the gender effect. Perhaps developmental TCDD 
exposure or AHR activation has a different effect in females than in males. TCDD 
is a known estrogen disruptor (Safe et al., 1998), and all mothers were HZ, so 
AHR+. Our rapid AHR genotyping allowed us to pool fetal livers to increase yield 
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of HSCs, but we did not genotype for fetal gender, so some alterations in 
response might also be gender-dependent. Any differences observed in the 
TCDD-exposed fetuses may have been modified by endocrine responses. 
Furthermore, without knowing fetal gender, we don’t know if one genotype group 
had more of a single gender, or, indeed, if the fetal survival is affected by gender. 
If TCDD, as an endocrine disruptor, biases the sex ratio within a litter, then the 
TCDD-exposed fetuses would have comprised a more uniform gender group 
without our knowledge. The lack of variability in the TCDD-exposed experiments 
supports this explanation. Similarly, it is possible that AHR is not required for 
gender determination, but its presence or absence may influence gender. Future 
work with these mice should incorporate fetal sex determination. 
There is increasing understanding that the intrauterine environment has 
great impact on the developing fetus. This applies not only to exposure to 
maternal nutrition and exposure to environmental contaminants, but potentially 
also to factors such as placement in the uterus. Most definitively, it has been 
shown that testosterone-related gender effects appear in mammal fetuses based 
on the gender of neighboring fetuses. Indeed, uterine position affects gender-
related anatomy such as anogenital distance (Ryan and Vandenbergh, 2002), 
physiology including levels of testosterone and estrogen (Vandenbergh and 
Huggett, 1994; vom Saal, 1989) and gender ratio of future offspring 
(Vandenbergh and Huggett, 1994), and behavior including novelty-seeking 
behavior (Palanza et al., 2001) and aggression (Ryan and Vandenbergh, 2002). 
Furthermore, in rats this effect is enhanced by a single gestational dose of TCDD 
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(Timms et al., 2002). This concept, known as the “womb-mate effect,” has been 
examined in other phenotypes as well. For example, murine fetal circulation is 
negatively affected by gestational location near a dead/reabsorbed fetus or a 
fetus with a different genotype (Raz et al., 2012). Because our litters were mixes 
of WT, HZ and KO fetuses, in some cases a KO might have been located 
between two WT or HZ fetuses in the uterus. Given the fact that AHR is involved 
in multiple developmental pathways, even though the KO fetus lacked any AHR 
alleles, its proximity to an AHR+ fetus (or a reabsorbed fetus) might have 
affected its development and therefore the response of its HSCs. Interestingly, 
our results from the limiting dilution analyses using HSCs from vehicle-exposed 
fetuses (Fig. 19B) did not fit the ELDA model as well as those from TCDD-
exposed mice (Fig. 19A). It is possible that some of the intrauterine effects 
described here were responsible for the variability seen from experiment to 
experiment in vehicle-exposed mice. When developmental TCDD exposure was 
added into the mix, it became the predominant determinant of HSC fate, 
overriding lesser effects based on gender or uterine position.  
Overall, the evolution of AHR appears to benefit longevity in multiple ways 
(Hirabayashi and Inoue, 2009), and therefore it should not be surprising that the 
AHR KO model that we used for our research had numerous complications. One 
way to overcome these difficulties would be to switch to a mouse model that is a 
conditional knock-out, which maintains the functionality of AHR for fertility, 
development, and general longevity, but that lacks the AHR in hematopoietic 
cells. This would allow our observations to focus on the hematopoietic effects, 
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and also decrease the number of mice required to reach significant power in our 
experiments. 
The experiments outlined in this chapter provide the first steps in 
definitively showing that the decreased lymphocyte differentiation following 
developmental TCDD exposure that our lab previously observed (Ahrenhoerster 
et al., 2014) is brought about due to the presence and activation of AHR in the 
fetus. Many of these findings will drive future work in the lab in terms of 
understanding the limits of the AHR full KO model and can increase the 
usefulness of limiting dilution analysis in testing developmental immunotoxicity of 
other environmental contaminants. 
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ABSTRACT 
 
Over half of T-cell acute lymphoblastic leukemia (T-ALL) patients have 
activating mutations in the Notch gene.  Moreover, the contaminant 2,3,7,8 
Tetrachlorodibenzo-p-dioxin (TCDD) is a known carcinogen that mediates its 
toxicity through the aryl hydrocarbon receptor (AHR), and crosstalk between 
activated AHR and Notch signaling pathways has previously been observed. 
Given the importance of Notch signaling in thymocyte development and T-ALL 
disease progression, we hypothesized that the activated AHR potentiates 
disease initiation and progression in an in vivo model of Notch1-induced 
thymoma. This hypothesis was tested utilizing adult and developmental exposure 
paradigms to TCDD in mice expressing a constitutively active Notch1 transgene 
(NotchICN-TG). Following exposure of adult NotchICN-TG mice to a single high dose 
of TCDD, we observed a significant increase in the efficiency of CD8 thymocyte 
generation. We next exposed pregnant mice to 3µg/kg of TCDD throughout 
gestation and lactation to elucidate effects of developmental AHR activation on 
later-life T cell development and T-ALL-like thymoma susceptibility induced by 
Notch1.  We found that the vehicle-exposed NotchICN-TG offspring have a 
peripheral T-cell pool heavily biased toward the CD4 lineage, while TCDD-
exposed NotchICN-TG offspring were biased toward the CD8 lineage. Furthermore, 
while the vehicle-exposed NotchICN-TG mice showed increased splenomegaly 
and B to T cell ratios indicative of disease, mice developmentally exposed to 
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TCDD were largely protected from disease. These studies support a model 
where developmental AHR activation attenuates later-life Notch1-dependent 
impacts on thymocyte development and disease progression.  
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INTRODUCTION 
 
In humans, rates of chronic immune diseases and disorders have 
progressively increased over the last forty years (Bach, 2002; Dietert et al., 2010; 
Howlader et al., 2013; Jacobson et al., 1997). Some have suggested the 
increase in immunodeficiencies is due to the interaction of the environment with 
genetic susceptibility factors leading to altered immune state or immune cell 
development (Fazekas de St Groth, 2007; Perl, 2010).  Environmentally initiated 
alterations in developmental pathways may lead to latent disease risk that can 
emerge at any time later in life following secondary exposures (Barker, 2007; 
Gluckman, Peter D. et al., 2005; Schug et al., 2012). Therefore, children are 
more vulnerable than adults to such exposures, as they have the entire life 
course ahead of them, resulting in more opportunities to impact sensitive time 
points (Perera and Herbstman, 2011). Environmental factors that are present 
during early life developmental stages may have particularly long-ranging impact 
by developmentally reprogramming progenitor cells through epigenetic changes 
at the chromatin level that potentially impact gene expression later in life. The 
impacts of progenitor cell reprogramming on later-life disease susceptibility are 
dependent on the interaction between the maternal intrauterine environment, the 
timing of exposure to potential insults, and the genetic susceptibility of the child. 
For example, early mutations in hematopoietic stem cells can increase the risk 
for development of leukemia (Corces-Zimmerman and Majeti, 2014). Moreover, 
60% of all cases of T cell acute lymphoblastic leukemia (T-ALL) are associated 
with activating genetic mutations in Notch1 (Van Vlierberghe and Ferrando, 
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2012; Weng et al., 2004), a transmembrane receptor required for T cell 
development and function and regulation of CD4 vs. CD8 lineage commitment 
(Fowlkes and Robey, 2002).  
Pinpointing environmental exposures as risk factors linked directly to 
disease outcomes is often complicated because of the latency associated with 
chronic, low level exposures.  However, developmental exposure to the 
ubiquitous, persistent contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 
acting through the aryl hydrocarbon receptor (AHR), has been connected to 
immune dysfunction later in life (Dietert, 2009; Vorderstrasse et al., 2004), and 
epidemiological studies that have followed the population in Seveso, Italy 
accidentally exposed to TCDD in 1976, show an increase in both lymphatic and 
hematological cancers in adults (Consonni et al., 2008).  Furthermore, children 
whose parents had elevated TCDD in their serum exhibited a decrease in thyroid 
function (Eskenazi et al., 2010). These results suggest that the adverse effects of 
TCDD can occur following both acute adult exposure and chronic low level 
developmental exposure and that the developing immune system is a sensitive 
target of TCDD in humans. 
A potential connection between the AHR and Notch was elucidated in 
human acute lymphoblastic leukemia (ALL) where hypermethylation of the AHR 
promoter region was observed (Mulero-Navarro et al., 2006).  Additionally, AHR 
responsive elements (AHREs) have been found in Notch promoters (Bock, 
2013), and Notch signaling induces stimulation of the AHR  in activated T cells 
(Alam et al., 2010).  However, whether Notch1 and developmental AHR 
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activation interact to promote disease has yet to be determined.  This potential of 
developmental Notch1-AHR crosstalk during hematopoietic system disease 
initiation warrants further consideration given the genetic link to Notch1 mutations 
in T-ALL and continued production and persistence of TCDD and other 
environmental combustion by-products that act on the AHR, particularly in many 
developing countries undergoing rapid industrialization (Tanabe and Minh, 2010; 
Terauchi et al., 2009; Tue et al., 2013). 
Previously we have demonstrated that developmental exposure to TCDD 
decreases the ability of hematopoietic progenitor cells to differentiate into mature 
lymphocytes (Ahrenhoerster et al., 2014).  To determine if this phenomenon 
could have later-life disease implications, we examined the effect of prenatal 
AHR activation by transplacental exposure to TCDD on development and 
progression of a Notch1-induced thymoma in mice. We utilized a Notch1 
transgenic mouse prone to developing T cell thymoma in order to probe a 
potential Notch1-AHR gene-environment interaction in disease. We hypothesized 
that developmental activation of AHR would produce a more severe form of 
Notch1- influenced thymoma in transgenic mice prone to disease than in 
unexposed control transgenic mice. To test this hypothesis, timed pregnant dams 
were exposed to 3µg/kg TCDD or vehicle control throughout pregnancy and at 
two days past parturition (PPD2).  We found that while there was no significant 
difference in disease onset, severity or incidence between the groups, there was 
a significant difference in the ratios of circulating T-cells in the adult mice 
developmentally exposed to TCDD, ultimately impacting the lineage of the 
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thymomas identified in the peripheral immune organs. Specifically, whereas 
unexposed Notch1 transgenic mice had a higher proportion of circulating CD4+ 
cells in the blood, Notch1 transgenic mice exposed to TCDD in utero had an 
increased proportion of circulating CD8+ cells as adults.  This T cell lineage 
switch suggests an AHR-dependent reprogramming of a hematopoietic precursor 
during development that impacts the later-life intrinsic Notch signal transduction 
occurring in the CD4 versus CD8 T-cell lineage choice. These data have 
implications for disease susceptibility in vulnerable populations that may possess 
genetic instability in the Notch locus and/or have been exposed to environmental 
AHR agonists developmentally.   
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RESULTS 
Notch1ICN-TG-dependent maturation of CD8+ thymocytes is potentiated by TCDD 
activation of the AHR. 
In order to elucidate the potential interaction between Notch1 and the AHR 
during thymocyte development, we exposed four-week old Notch1ICN-TG and 
C57BL/6 mice to a single dose of 10 or 30µg/kg TCDD or vehicle control, and 
analyzed thymus size, cell number, and composition 10 days after exposure. The 
Notch1ICN-TG transgenic mice utilized for these studies expresses the 
constitutively active intracellular Notch1 under control of the lck-proximal 
promoter, restricting its expression to developing thymocytes.  These mice have 
previously been shown to produce a larger percentage of CD8+ thymocytes than 
CD4+ thymocytes, in contrast to proportions found in wild type C57BL/6 mice 
(Robey et al., 1996). This increased population of CD8+ cells found in the 
Notch1ICN-TG thymus is similar to observations made in mice exposed to the AHR 
ligand TCDD (Gill et al., 2008; Kremer et al., 1995). Following exposure to 
TCDD, both C57BL/6 and Notch1ICN-TG mice showed a significant decrease in 
thymic weight and cellularity (Fig. 22A-B).  Notably, we found that vehicle-
exposed adult Notch1ICN-TG mice had larger thymuses by weight (Fig. 22A) but 
lower cellularity (Fig. 22B) than C57BL/6 mice.  Examination of flow cytometry 
FSC-A histograms for cell size distribution show a bi-modal peak in Notch1ICN-TG 
mice compared to the C57BL/6 indicating there is a greater population of large 
blast-like thymocytes (Fig. 23).  
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Figure 23.  Thymocytes from Notch1ICN-TG mice exhibit a bimodal forward scatter 
histogram. Thymocytes were isolated from Notch1ICN-TG and C57BL/6 mice, then 
analyzed on a BD FACS Aria III flow cytometer for forward scatter, a measure of cell 
size A) representative plot of thymocytes in female mice  B) representative plot of 
thymocytes in male mice; Black histogram represents C57BL/6 mice and red histogram 
represents Notch1ICN-TG mice.  Figure originally included as supplementary for Chapter 5 
publication. 
Figure 22: Thymus cellularity and efficiency of thymocyte conversion in adult male 
C57BL/6 or Notch1ICN-TG mice after administration of TCDD or vehicle control. Wild 
type C57BL/6 or Notch1ICN-TG mice were administered 10µg/kg TCDD, 30µg/kg TCDD or 
vehicle control via oral gavage at 4 weeks of age.  Ten days later, mice were euthanized, 
thymuses removed, single cell suspensions made, and cells stained with fluorescent-
conjugated antibodies directed against CD4 and CD8.  Cells were acquired on a BD FACS 
Aria III flow cytometer and data analyzed in FlowJo.  A) Thymus weight ± SEM; B) 
Thymocyte cellularity ± SEM; C-F) Absolute cell number (mean ±	 SEM) in each thymocyte 
cell population; G-H) Efficiency of SP (CD4+ or CD8+) generation, calculated by dividing 
the number of CD4+ or CD8+ thymocytes in by the number of CD4+CD8+ precursors; 
Vehicle mice are represented with white bars, 10µg/kg TCDD mice with black bars, and 
30µg/kg TCDD-exposed mice with gray bars. A single * indicates p≤0.05; ** indicates 
p≤0.01; *** indicates p≤0.001.  All compared to vehicle control within genotype unless 
otherwise indicated by bracket.  (n=at least 4 B6 mice in each group; n=at least 8  
Notch1ICN-TG mice in each group) 
C57BL/6 mice 
 
Notch1ICN-TG mice 
A. 
B. 
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Analysis of thymocyte sub-populations revealed effects dependent on 
either Notch1ICN-TG, TCDD activation of the AHR, or on the combination of 
Notch1ICN-TG and TCDD activation of the AHR. Specifically, we found that in both 
C57BL/6 and  Notch1ICN-TG  mice, TCDD-activation of the AHR led to a significant 
decrease in the absolute number of the most immature population of thymocytes 
identified by the absence of both CD4 and CD8 (Fig 22C). The largest population 
of thymocytes by cell number, the CD4+CD8+, is reduced in number by more 
than 10 fold in the C57BL/6 mice after exposure to TCDD as previously reported 
(Fig 22D; p≤0.001; Laiosa et al., 2003, 2002).  Moreover, CD4+CD8+ thymocyte 
numbers in Notch1ICN-TG are also reduced by approximately 10 fold (p≤0.05), 
however, the number of CD4+CD8+ thymocytes in the vehicle-exposed 
Notch1ICN-TG is 10 fold lower than vehicle-exposed C57BL/6, suggesting that the 
intracellular Notch1 transgene alters the basal thymocyte cell number. In 
comparison to the reduction observed in CD4+CD8+ thymocytes, the production 
of CD4+ and CD8+ progeny that result from positive selection are differentially 
sensitive to the combined effects of Notch1ICN-TG and the TCDD-activated AHR. 
Specifically, while the number of CD4 lineage thymocytes is significantly reduced 
by exposure to TCDD in both C57BL/6 and Notch1ICN-TG mice (Fig 22E), CD8+ 
cells are present in equal number in the vehicle- and TCDD-exposed Notch1ICN-
TG mice (Fig 22F). Given the differences in thymocyte cell number between 
C57BL/6 and Notch1ICN-TG mice, we used a ratio of single positive CD4+ or CD8+ 
to CD4+CD8+ as a way to normalize the efficiency of thymocyte conversion. 
Typically, 95-99% of CD4+CD8+ thymocytes fail selection, which is reflected by 
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ratios of less than 0.2 in the C57BL/6 mice. In comparison, the thymocyte 
conversion efficiency in Notch1ICN-TG mice is 3 to 5 fold higher in the CD4 and 
CD8 lineages, respectively. Moreover, 30µg/kg TCDD produces an excess of 
CD8 cells compared to DP cells thus yielding a ratio of CD8+ to CD4+CD8+ cells 
that is greater than one, indicating an increase in CD8 conversion efficiency in 
Notch1ICN-TG mice (Fig 22H; p≤0.05). These results suggest a potential additive 
interaction between the thymocyte-restricted constitutively active intracellular 
Notch1 and the ligand-activated AHR during thymocyte development.  
Developmental Exposure to TCDD Does Not Affect Survival Into Adulthood of 
Notch1ICN-TG transgenic mice. 
Based on our recent findings linking developmental TCDD exposure to 
attenuation of Notch1-dependent lymphocyte differentiation (Ahrenhoerster et al., 
2014), and previous work demonstrating that developmental AHR activation 
adversely impacts later life immunity (Hogaboam et al., 2007),  we hypothesized 
that developmental AHR activation by TCDD reprograms hematopoietic 
progenitor cells such that susceptibility to later-life genetically-based T-cell 
leukemia-like disease is increased. We tested this hypothesis in T-cell thymoma 
prone NotchICN-TG mice by initially following the survival of Notch1ICN-TG mice 
exposed to either vehicle or 3µg/kg of TCDD throughout gestation (GD 0.5, 7.5, 
14.5 and PPD 2.5). The in utero and lactationally-exposed pups were followed 
until death or 12 weeks of age.  Although approximately 40% of Notch1ICN-TG 
mice died during the experiment, there was no significant difference in overall 
survival between TCDD- or vehicle-exposed Notch1ICN-TG mice (Fig. 24).   
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Figure 24:  Survival of C57BL/6 or Notch1ICN-TG mice following developmental 
exposure to 3µg/kg TCDD or vehicle control.  Pregnant C57BL/6 dams (paired with 
either C57BL/6 or Notch1ICN-TG males) were exposed to 3µg/kg TCDD or vehicle control 
throughout gestation (GD0.5, GD7.5, GD14.5, PPD2.5).  Resulting offspring were 
followed through twelve weeks of age to determine age of death.  C57BL/6 mice are 
represented with a black line (vehicle and TCDD; n=35). Notch1ICN-TG mice are 
represented with a red line (vehicle; n=72) or blue line (TCDD; n=63).  Survival fractions 
were calculated using Kaplan-Meier analysis, and survival curves were compared using 
the log-rank (Mantel-Cox) test (C57BL/6 p=1.00; Notch1ICN-TG p=0.62).   
 
 
Developmental TCDD exposure in Notch1ICN-TG mice skews blood B cell to T cell 
and CD4 to CD8 ratios in adult mice. 
It is well established that Notch1ICN-TG mice have an altered ratio of CD4+ 
to CD8+ T cells compared to non-transgenic mice (Fowlkes and Robey, 2002; 
Robey et al., 1996), but the combined effect of developmental exposure to AHR 
agonists such as TCDD had not been examined in these mice.  In order to more 
specifically quantify differences in thymoma initiation and progression following 
developmental exposure to TCDD in Notch1ICN-TG mice, we collected blood 
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samples each week between 5 and 12 weeks of age, and quantified the 
proportions of circulating lymphocytes (Fig. 25A-C). No significant difference was 
found between treatments at any time point in either C57BL/6 or Notch1ICN-TG 
mice in the percentage of macrophages and granulocytes, as evidenced by 
percent of CD11b+ or Gr1+CD11b+ cells, respectively (Fig. 25A, B & G).  
Similarly, we found no significant difference between vehicle or TCDD exposure 
in the ratio of B cells to T cells or in CD4+ T cells to CD8+ T cells in the C57BL/6 
mice (Fig. 25C & H). However, in Notch1ICN-TG mice, we saw a significantly lower 
ratio of B cells to T cells following developmental exposure to TCDD (Fig. 25D & 
H).  Additionally, we saw a significantly lower ratio of CD4+ T cells to CD8+ T 
cells in mice developmentally exposed to TCDD (Fig 25F & I).  Notably, in 
Notch1ICN-TG mice, the ratio of B cells to T cells, and the ratio of CD4+ to CD8+ T 
cells in mice developmentally exposed to TCDD decreased almost to the level 
found in C57BL/6 mice.  These data suggest that developmental exposure to 
TCDD provides protection from the alterations caused by a constitutively active 
Notch1 in thymocytes.  
To determine if the change in the CD4+ to CD8+ ratio following 
developmental TCDD exposure could be explained by preferential survival of the 
CD8+ cells, we used the TUNEL assay to compare apoptosis in the thymus of 8 
week old mice.  We found no significant difference in the survival of CD4+ cells, 
CD8+ cells, or CD4+CD8+ cells following developmental TCDD exposure in 
either gender of mice (Fig. 26).    
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Figure 25:  Proportion circulating lymphocytes in the blood following 
developmental exposure to 3µg/kg TCDD or vehicle control. Pregnant C57BL/6 
dams (after pairing with either C57BL/6 or Notch1ICN-TG males) were exposed to 3µg/kg 
TCDD or vehicle control throughout gestation (GD0.5, GD7.5, GD14.5, PPD2.5). A-F) 
Representative flow cytometry plots from week 8 blood samples, illustrating distribution 
and analysis of CD11b and Gr-1 positive cells (A), CD3+ T cells and CD19+B cells (C & 
D), and CD8+ and CD4+ T cells, gated on CD3+ (E & F). Frequency of Gr1+CD11b+ 
blood cells (G), the ratio of B cells to T cells in blood (H), or the ratio of CD4+ T cells to 
CD8+ T cells in blood (I) in both C57BL/6 mice (graphs on left) and Notch1ICN-TG (graphs 
on right).  Vehicle treated mice are represented by a white bar and mice treated with 
TCDD are represented by a filled bar in G-I. Bars graph mean with SE.  A single * 
indicates p≤0.05; ** indicates p≤0.01; *** indicates p≤0.001. 
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Figure 26.  Percentage of apoptotic thymocytes in Notch1ICN-TG mice are not 
significantly different following developmental exposure to vehicle control or 
3µg/kg TCDD. Notch1ICN-TG mice were exposed to 3µg/kg TCDD or vehicle control on 
GD 0.5, 7.5, 14.5 and PPD 2.5.  Thymuses were harvested from 8 week old mice and a 
TUNEL assay was used to determine percentage of cells undergoing apoptosis. A) 
CD4+ thymocytes;  B) CD8+ thymocytes; C) Double positive (CD4+CD8+) thymocytes.  
Figure originally included as supplementary for Chapter 5 publication.  
 
Peripheral thymomas in Notch1ICN-TG mice following developmental TCDD 
exposure exhibit altered B cell:T cell ratios and differential expression of CD5. 
The spleen is almost always involved in murine leukemia and neoplasms 
(Yang et al., 2013) thus we further examined splenic tissue to search for 
metastatic thymomas.  We observed alterations in the B cell to T cell ratio in 
spleens (Fig. 28), similar to that found in blood (Fig. 25). Specifically, TCDD-
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exposed C57BL/6 mice showed a significantly lower B cell to T cell ratio 
difference at 8 weeks (Fig. 28A & E; p≤0.01). Notch1ICN-TG mice also showed a 
significant decrease in the ratio of B cells to T cells following developmental 
exposure at both 8 weeks (p≤0.001) and 12 weeks (p≤0.05) of age (Fig. 28B, D 
& E).  Although both week 8 C57BL/6 and weeks 8 and 12 Notch1ICN-TG mice 
showed significant differences in B cell to T cell ratios, the magnitude of 
difference in Notch1ICN-TG mice was much greater.  Whereas in C57BL/6 mice, 
the ratio decreased by 30 percent (2.7 in vehicle-exposed to 1.9 in TCDD-
exposed), in Notch1ICN-TG mice, the ratio decreased over 50 percent at week 8 
(23.6 in vehicle-exposed to 11.4 in TCDD-exposed) and over 60 percent at week 
12 (9.7 in vehicle-exposed to 3.3 in TCDD-exposed).  
We further measured CD5 expression in CD4+ and CD8+ splenic T cells 
as a proxy for T cell activation (Fig. 28F).  We found the mean fluorescence 
intensity (MFI), an indication of the density of CD5 on the cell surface, was nearly 
two-fold lower in the CD8+ population.  However, in both the CD4+ and CD8+ 
populations, cells from mice developmentally exposed to vehicle control had 
greatly decreased MFI.  Additionally, in both cases, MFI in cells isolated from 
spleens of Notch1ICN-TG mice developmentally exposed to TCDD returned to near 
the MFI levels seen in C57BL/6 mice. These data show that   Notch1ICN-TG mice 
developmentally exposed to TCDD approach a B cell to T cell ratio and a CD5 
MFI similar to the wild type C57BL/6 vehicle-exposed mice. 
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Figure 27:  CD4 and CD8 cell proportions in thymus are not significantly different 
following developmental exposure to 3µg/kg TCDD or vehicle control. Pregnant 
C57BL/6 dams (paired with either C57BL/6 or Notch1ICN-TG males) were exposed to 
3µg/kg TCDD or vehicle control throughout gestation (GD0.5, GD7.5, GD14.5, PPD2.5).  
A) Representative flow cytometry plots from week 8 thymus samples; B)  Ratios of B 
cells to T cells at 8 weeks and 12 weeks, with C57BL/6 mice on the left and Notch1ICN-TG 
mice on the right; C) Frequency of viable cells (defined by absence of sytox blue stain) in 
double positive (CD4+CD8+) quadrant of flow cytometry plots. Vehicle treated mice are 
represented by a white bar and mice treated with TCDD are represented by a filled bar 
in B-C. Bars graph mean with SE. (n=3 C57BL/6 vehicle; n=3 C57BL/6 TCDD; n=8 
Notch1ICN-TG vehicle; n=7 Notch1ICN-TG TCDD at week 8; n=4 C57BL/6 vehicle; n=5 
C57BL/6 TCDD; n=6 Notch1ICN-TG vehicle; n=8 Notch1ICN-TG TCDD at week 12);  
C57BL/6 mice are pictured on the left.  Notch1ICN-TG mice are pictured on the right.  
Figure originally included as supplementary for Chapter 5 publication. 
B. 
A . 
 
C. 
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Figure 28:  Cell proportions in spleen are altered following developmental 
exposure to 3µg/kg TCDD or vehicle control. Pregnant C57BL/6 dams (paired with 
either C57BL/6 or Notch1ICN-TG males) were exposed to 3µg/kg TCDD or vehicle control 
throughout gestation (GD0.5, GD7.5, GD14.5, PPD2.5). A and C) Representative flow 
cytometry plots delineating B and T cells from weeks 8 and 12 C57BL/6 spleen samples; 
B and D) Representative splenic B versus T cell flow cytometry plots from weeks 8 
and12 in Notch1ICN-TG; E) Ratios of B cells to T cells at 8 weeks and 12 weeks, with 
C57BL/6 mice on the left and Notch1ICN-TG mice on the right;  F) Mean fluorescence 
intensity of CD5 in T-cells from 6-8 week old mice, within the CD4 population on the left 
and the CD8 population on the right; Vehicle treated mice are represented by a white bar 
and mice treated with TCDD are represented by a filled bar in D-E. Bars graph mean 
with SE.  A single * indicates p≤0.05; ** indicates p≤0.01; *** indicates p≤0.001. (n=3 
C57BL/6 vehicle; n=3 C57BL/6 TCDD; n=8 Notch1ICN-TG vehicle; n=7 Notch1ICN-TG TCDD 
at week 8; n=4 C57BL/6 vehicle; n=5 C57BL/6 TCDD; n=6 Notch1ICN-TG vehicle; n=8 
Notch1ICN-TG TCDD at week 12). 
 
 
  
  
 
123 
Spleen size was significantly smaller in Notch1ICN-TG mice following 
developmental TCDD exposure than in vehicle controls.  
 Upon necropsy, many of the vehicle control Notch1ICN-TG mice had 
enlarged spleens--a sign of leukemic infiltration (Zhang et al., 2013) and this 
enlargement was much more common and severe in vehicle mice than in 
developmentally TCDD-exposed Notch1ICN-TG mice. Specifically, we found a 
statistically significant difference in spleen weight, size and length between the 
exposed and control groups (p≤0.01; Fig. 29A-C).  Furthermore, we used a 
numerical grading system in order to insure that spleens exhibiting severe 
splenomegaly did not bias the mean values shown in Fig. 29A-C. As previously 
published (Duggan et al., 2012), the grading system categorized spleens into 
grades 1-4 based on the following weights:  normal (<0.2 g; Grade 1), moderate 
enlargement (≥0.2 - <0.5g; Grade 2), severe enlargement (≥0.05 - <1.0g;    
Grade 3), or morbid enlargement (≥1.0g; Grade 4). Whereas over 80% of 
spleens in the gender-combined TCDD-treated group fell into the “normal spleen” 
range, less than half of those in the vehicle group could be categorized as normal 
(Fig. 29D).  Furthermore, this effect was even more pronounced in the female 
Notch1ICN-TG mice.  None of the C57BL/6 wild type mice used in this experiment 
exhibited any spleen enlargement, supporting presence of metastatic thymomas 
as the cause of splenomegaly.  
 
  
 
124 
 
Figure 29:  TCDD-exposed Notch1ICN-TG mice fail to develop Notch1-mediated 
splenomegaly. Developmental exposure to TCDD in Notch1ICN-TG mice results in 
significantly smaller adult spleen size.  Pregnant C57BL/6 dams were paired with 
Notch1ICN-TG males and exposed to 3µg/kg TCDD or vehicle control throughout gestation 
(GD0.5, GD7.5, GD14.5, PPD2.5). Vehicle treated mice are represented by a white bar 
and mice treated with TCDD are represented by a filled bar. Bars graph mean with SE.  
A single * indicates p≤0.05; ** indicates p≤0.01; *** indicates p≤0.001. Comparisons of 
spleen weight (A), length (B), and width (C) were all made on 8 week old mice; spleen 
grading was done across all mice between 8-12 weeks of age at any age of necropsy.  
(n= 38 vehicle and 23 TCDD mice in A-C; n=61 vehicle and 52 TCDD mice in D) 
 
 
 
 
 
 
  
  
 
125 
DISCUSSION 
 
 
In the present study, we demonstrate that developmental exposure to the 
environmental contaminant and AHR agonist TCDD during development in 
Notch1-dependent thymoma-prone mice reprograms long-term HSCs such that 
the adult thymic progeny of these cells have an attenuated response to the 
Notch1-dependent CD4 versus CD8 lineage decision. Specifically, the unusually 
large CD4:CD8 ratio observed in Notch1ICN-TG mice is restored to nearly C57BL/6 
wild-type levels in the Notch1ICN-TG TCDD-exposed offspring. These data are 
therefore consistent with the conclusion that developmental AHR activation 
provides a means of disease protection to mice possessing a Notch1-mediated 
propensity to develop leukemic thymomas.  
We have previously shown that developmental exposures to TCDD 
reprogram long-term reconstituting HSCs, impacting their ability to complete 
lymphocyte lineage commitment (Ahrenhoerster et al., 2014). These studies 
extend the impact of AHR-induced HSC reprogramming by demonstrating a long-
term attenuated response to Notch1-mediated T-cell differentiation evidenced by 
the CD4 to CD8 lineage switch observed in peripheral T-cells from offspring 
exposed to TCDD during development. Taken together, these data are 
consistent with the conclusion that in a progenitor cell population in the fetus 
there are epigenetic or stable changes to the chromatin influenced by AHR 
activation that have later-life impacts on gene expression and cellular 
differentiation. Notably, the impact of this reprogramming on hematopoietic 
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differentiation is not readily apparent in wild type C57BL/6 mice. Rather, for the 
later-life alterations to produce a measurable change in cellular function, the 
progeny of the long-term progenitor cells need to differentiate and be challenged 
by a secondary stressor such as the constitutively active intracellular Notch 
transgene in the thymus.   
The acute exposure experiment demonstrated an increase in CD8 
conversion efficiency following TCDD exposure in both C57Bl/6 and Notch1ICN-TG 
adult mice in the thymus, though not in the periphery (data not shown), providing 
initial evidence of potential AHR-Notch crosstalk. However, the substantial thymic 
atrophy resulting from adult TCDD exposure complicated interpretation of the 
mechanism for the increase in CD8+ cell conversion efficiency. Thus the switch 
to a developmental exposure model combined with a 10-fold decrease in dose 
throughout gestation allowed us to more clearly elucidate the effect that AHR 
activation had on Notch signal transduction throughout the lifecourse.   Using this 
developmental model, any TCDD-induced thymic atrophy that occurred in fetal or 
neonatal mice was resolved by adulthood as indicated by similar thymic CD4+ 
and CD8+ populations as adults. Thus, the long-term developmental studies 
identified more sensitive and longer lasting outcomes than the adult exposure 
experiments.  Specifically, developmental TCDD-exposure affected peripheral T-
cell homeostasis demonstrated by a significant change in the efficiency of 
generating post-selection CD8+ T cells. 
One interpretation of this study could be that early life AHR activation by 
TCDD is actually beneficial for Notch-mediated hematopoietic disease. However, 
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Notch signaling is crucial for fetal HSC development and proliferation, for T 
lineage choice (Bigas and Espinosa, 2012), and for normal T cell development in 
both the fetus and adult (Osborne and Minter, 2007; Schmitt and Zúñiga-
Pflücker, 2002).  Therefore, impairment of physiological Notch signaling in HSCs 
and T cells has the potential to alter normal development and the consequences 
of this attenuation could impact a spectrum of hematological-based diseases.   
Physiological Notch1-dependent signal transduction is characterized by 
engagement of the extracellular portion of Notch with Jagged or Delta-like 
ligands on a neighboring cell.  This protein-protein engagement results in the 
gamma secretase-mediated cleavage of the intracellular Notch1 (ICN) domain. 
The ICN translocates into the nucleus and associates with the CBF1/Su(H)/Lag-1 
(CSL) transcription factor complex where it acts as a co-activator driving 
transcription of a broad array of genes, including those responsible for T cell 
lineage commitment. A potential consequence of ICN over-expression in 
Notch1ICN-TG mice could be that the transgene stoichiometrically saturates the 
CSL binding site in the Notch signaling pathway leading to aberrant gene 
regulation attenuating physiological Notch activity (Beres et al., 2006). The 
importance of the transgenic ICN saturation of the CSL binding site in our studies 
follows the knowledge that physiological Notch1 is an AHR-regulated gene 
(Stevens et al., 2009). Though it is not known whether Notch transcription is 
directly controlled by the AHR (Kiss and Diefenbach, 2012), our data suggests 
that AHR activation during development leads to a change in responsiveness to 
ICN-mediated T cell development that persists throughout the life course.   
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Despite equivalent survival rates between Notch1ICN-TG mice 
developmentally exposed to TCDD or vehicle (p=0.62), the fatality rate in vehicle-
exposed Notch1ICN-TG mice was higher than the 20% tumor rate previously 
reported at 5 months (Beverly and Capobianco, 2003). It is unknown whether the 
propensity for thymoma development increased in our sub-strain of Notch1ICN-TG 
mice prior to arriving in our vivarium, or was selected for inadvertently from our 
original breeder pair. However, this increased spontaneous thymoma rate made 
it difficult to form a conclusion about the original hypothesis that developmental 
TCDD exposure would increase later-life disease susceptibility. Nevertheless, the 
altered T cell ratios in the blood and splenomegaly differences are consistent 
with the conclusion that developmental TCDD exposure impacts Notch1-
dependent disease initiation. 
In terms of the splenomegaly, the expected result that tumor-resistant 
C57BL/6 mice survived for the duration of the 12-week experiment without 
splenomegaly, indicates that the enlarged spleens are unique to the transgenic 
strain we used and not due to the developmental TCDD exposure.  The 
moderate protection against splenomegaly by developmental TCDD is similar to 
autoimmune and inflammatory amelioration following AHR activation (Busbee et 
al., 2013; Di Meglio et al., 2014; Kerkvliet, 2009). These data raise the intriguing 
possibility that AHR modulators could have efficacy as chemopreventatives or 
chemotherapeutics in certain types of leukemia, particularly if combined with 
existing treatments allowing for the decreasing of current doses.  For example, 
gamma-secretase inhibitors (GSIs) that block Notch activation are a promising 
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recent treatment for T-ALL, however, the negative side-effects include dose-
limiting diarrhea (Hernandez Tejada et al., 2014; Takebe et al., 2014).  
In addition to the CD4 to CD8 ratio changes mediated by developmental 
TCDD exposure, we also observed alterations in the CD5 MFI in both CD4+ and 
CD8+ splenic T cells. Specifically, CD5 levels, as determined by MFI, were 
significantly decreased in vehicle-exposed Notch1ICN-TG mice when compared to 
C57BL/6 mice (Fig. 5E).  However, following developmental exposure to TCDD, 
the MFI of CD5 in both CD4+ and CD8+ T cells is partially restored to C57BL/6 
levels. The consequences of the lower CD5 expression is consistent with a 
model of higher TCR signal transduction in T cells from Notch1ICN-TG mice 
(Germain, 2002), leading to a potential increase in activation-induced cell death 
in the periphery. While we were not able to detect any increases in apoptosis in 
vivo (supplemental figure 3), we and others have previously reported the difficulty 
in measuring apoptosis in vivo due to rapid clearance by macrophages (Laiosa et 
al, 2007). Thus we relied on indirect observations, such as splenomegaly to 
support the hypothesis of increased activation-induced cell death given that 
spleen enlargement is consistent with the removal of dead and dying cells. 
Moreover, elevated removal of dead and dying cells as occurs in a number of 
hematological disorders, including leukemia and lymphoma, is a hallmark of 
disease.  Taken together, the developmental TCDD-dependent increase in CD5 
expression in T cells from Notch1ICN-TG mice and the reduction in splenomegaly 
in TCDD-exposed Notch1ICN-TG mice supports a model of inhibition of T cell 
activation later in life. 
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While developmental AHR activation offers protection from later-life CD4+ 
to CD8+ T cell ratio imbalance and splenomegaly caused by constitutively-active 
ICN, the increase in CD8+ T cells that restores the ratio may not be beneficial in 
a more physiological model. Specifically, a decrease in the ratio of CD4+ T cells 
to CD8+ T cells in blood has been linked to poorer disease outcomes following 
diagnosis and treatment in several immunological diseases, including childhood 
leukemia (Lustfeld et al., 2014), hepatitis (Ikeda et al., 2012), and HIV (Serrano-
Villar et al., 2014).  We found that Notch1ICN-TG mice developmentally exposed to 
TCDD showed a persistently lower CD4+ to CD8+ ratio in peripheral blood, 
suggesting a less favorable response to disease treatment.   
In summary, our results indicate that prenatal exposure to the 
environmental toxicant and AHR agonist TCDD reprograms HSCs and 
significantly changing the course of disease in a Notch1-induced murine 
thymoma model, as measured by ratios of B cells to T cells, and CD4+ T cells to 
CD8+ T cells.  Future research on epigenetic changes influenced by exogenous 
stimulation of the AHR during development may provide insight into the spectrum 
of secondary exposures vulnerable populations are burdened with that increase 
their propensity for later-life hematological and other immune deficiencies. 
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It has long been known that TCDD is a ubiquitous environmental 
contaminant and carcinogen linked to disease in multiple systems. TCDD and 
related contaminants exert their toxicity through the AHR, a transcription factor 
which contributes to regulation of hematopoiesis, among its many functions. 
Hematopoiesis, the process by which all blood and immune cells are 
formed from HSCs, is a delicate balance between self-renewal and differentiation 
of HSCs. Given that HSCs are formed in utero, any alteration during gestation 
can have long-term effects on health. Development depends on numerous 
factors present (or absent) in the intrauterine environment, and there is growing 
knowledge that exposures in utero and soon after birth may have persistent, 
detrimental effects on health and disease which may not manifest until later in life 
(Fig. 30).  
In the research described here, we have shown that exposure to an 
environmentally-relevant level of TCDD in utero has effects on the developing 
immune system. In mice, the HSCs formed following developmental exposure to 
TCDD have a greatly diminished capacity to differentiate into T and B effector 
cells. Furthermore, we have shown that developmental TCDD exposure exerts 
this effect through the AHR in the fetus.  
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Figure 30. Exposure to TCDD in utero potentially affects offspring at particularly 
sensitive periods of development. This model illustrates the possible impact of 
developmental exposure to AHR-activating environmental contaminants, such as TCDD. 
TCDD exposure in the pregnant mother activates the AHR in the fetus, leading to a 
reprogramming of HSCs which we have shown attenuates the number of mature B cells, 
number of mature T cells, and ratio of CD4+ to CD8+ T cells. As the exposed fetus 
matures, at particularly sensitive timepoints such as childhood, puberty, during the 
reproductive years, and into older adulthood, the immune system formed from 
reprogrammed HSCs may result in an increase in the incidence of hematological 
diseases including, but not limited to, autoimmunity, immunosuppression, and cancer. 
 
While determining HSC differentiation potential, an interesting observation 
was made: although the ability of the HSCs isolated from exposed mice to 
differentiate into lymphocytes was significantly decreased, the number of HSCs 
isolated per fetus was increased. Interestingly, both alterations were 
approximately two and a half-fold, thus potentially canceling out the effect of 
either alone. Dysfunction in cell-cycle regulation should be explored to provide a 
clearer picture of the true long-term consequence of developmental exposures by 
determining the net quantity of functional effector cells produced.  
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Throughout this work, we have used the terms “LSK” and “HSC” 
somewhat interchangeably, but they are not technically the same. The cell 
surface markers that we used to identify HSCs (as LSKs) resulted in a 
heterogeneous mixture of ST- and LT-HSCs, potentially at different stages of 
lineage commitment when isolated. Additional cell surface markers, including the 
SLAM family (CD48, CD150, CD229, CD244) are known to identify HSCs earlier 
in the hierarchy of stem cell-ness and therefore with greater pluripotency (Oguro 
et al., 2013). Determining the differentiation potential of LT-HSCs isolated from 
fetal livers and comparing to the LSK potentials would help pinpoint the level at 
which TCDD-induced HSC re-programming is occurring. Impact on the myeloid 
lineage could also be examined to more closely focus the level of HSC hierarchy 
at which re-programming appears. 
Complete understanding of fetal HSC reprograming must include all sites 
of hematopoiesis as well as all maturation states.  The yolk sac and AGM are the 
site of hematopoiesis before the fetal liver is, and the placenta has also been 
suggested as a potential embryonic site of hematopoiesis (Golub and Cumano, 
2013). Testing the differentiation potential of HSCs isolated from these alternate 
embryonic sites of hematopoiesis, in conjunction with gene expression data, 
would expand our knowledge of the mechanism by which HSCs are 
reprogrammed during development. 
As a follow-up to our experiments showing decreased differentiation 
potential of HSCs following developmental AHR activation, we also have shown 
that, in a mouse model genetically prone to thymoma, environmental exposure to 
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TCDD radically changes the progression of disease as measured by CD4+ and 
CD8+ T lymphocyte levels in the blood and spleen.  Individual genetic variation in 
addition to epigenetic programming can interact with effects caused by 
environmental exposures during development. Polymorphisms or epigenetic 
reprogramming act in conjunction with developmental AHR activation and 
maternal health to produce the variability seen in disease development.  
Forming a functional immune system requires integration of self renewal, 
proliferation, differentiation, and activation of HSCs. The limiting dilution 
experiments that we used only determined lymphocyte differentiation potential of 
the HSCs isolated from developmentally-exposed mice. Although it was not 
determined that the decreased differentiation potential has a functional effect, we 
would expect that it would. While we observed changes in the course of disease 
following developmental exposure in Notch transgenic mice, we saw no 
significant impact in the wild type mice.  However, functionality of the 
lymphocytes that develop from HSCs developmentally exposed to TCDD could 
be tested in culture or after isolation from adult mice. Comparing cytokine 
baseline levels or levels after an immune response, or measuring changes in 
gene expression in either case may provide support for true functional impact.  
Though we only determined HSC differentiation potential, these findings 
still suggest considerable potential consequences on lifelong immunity. Because 
the adult immune system develops from HSCs, we would expect that 
developmental exposure also affects such immunological health outcomes as 
development of cancer or autoimmune diseases. Epidemiologically, rates of 
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immune diseases have risen in the last forty to fifty years, which coincides with 
industrialization, especially in developing countries. Others have shown that mice 
developmentally exposed to TCDD show a weakened immune response to 
influenza challenge (B A Vorderstrasse et al., 2004), which lends support to there 
being long-term consequences following early alterations in lymphocyte 
differentiation potential.  
Our research uses TCDD as an AHR agonist, but many other 
environmental contaminants, including PCBs, PAHs, and dibenzofurans, are also 
AHR ligands. Additionally, many of these substances exist environmentally as 
mixtures.  Though non-TCDD ligands are more readily metabolized and the 
resulting AHR activation is not as persistent, the possibility exists that 
developmental exposure to a combination of AHR ligands may cause similar or 
altered effects on T cell development or function.  An important next step would 
be to examine consequences of developmental exposure to a mixture of AHR 
ligands. 
In addition to exploring additional AHR ligands, it is important to 
investigate the impact of developmental TCDD exposure on additional body 
systems. Because the AHR is involved in a large number of developmental 
pathways, we would expect that gestational exposure to an AHR agonist would 
impact not only the hematopoietic system, but other systems as well. Exposure 
to an AHR agonist such as TCDD in utero might also cause long-term impact on 
the nervous system. In fact, migration of one type of stem cell, neural crest cells, 
has been shown to be altered by cigarette smoke acting through the AHR (Sanbe 
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et al., 2009). Additionally, neurons derived from umbilical cord blood stem cells 
express the highest levels of AHR and related genes early in development (A. K. 
Singh et al., 2013) and embryonic stem cells express AHR, which drives their 
differentiation into cardiomyocytes (Wang et al., 2013). The potential for AHR-
related effects following a developmental exposure are extensive and provide 
opportunities to expand the findings reported here for the immune system. 
Although we controlled for multiple variables, one of the variables that we 
did not take into account in this research was the gender effect. Research has, 
by convention, more often used male organisms in research studies (Clayton and 
Collins, 2014), and we initially followed this convention with the adult mice used. 
However, TCDD has endocrine disruption potential, and therefore could have 
potentially affected results by gender. Results might be biased in either direction, 
as, for example, developmental exposure to TCDD has been shown to feminize 
male rats (Ikeda et al., 2005), and to alter expression of more genes in ovaries 
than in testes (Magre et al., 2012). We did not genotype fetuses when harvesting 
HSCs from GD 14.5 livers, so each experiment contains HSCs from a mix of 
male and female. Future research might determine that the differences we found 
are more extreme when categorized by gender.  
Another variable which might benefit from tighter control is timing, or more 
specifically, circadian rhythm. Though our samples were all harvested within a 
two hour window, even within that window circadian differences might emerge. 
For timed pregnancies, mating may have occurred at any time within a 15 hour 
time period, and implantation might have varied as well. Finding a means to more 
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accurately time pregnancies, and keeping HSC harvest especially within a small 
timeframe might increase the strength of differences seen. 
Finally, we observed the greatest inconsistencies in results when working 
with AHR transgenic mice. After initial testing to determine response similarity 
between AHR+/+ (WT) and AHR+/- (HZ) mice, we eliminated WT mice from our 
experiments. Although HZ mice, by virtue of having an AHR allele, should 
respond to AHR activation in a manner similar to WT mice, there is a possibility 
that unknown factors may be present within the heterozygous population. 
Assaying all three genotypes—WT, HZ and KO—might illuminate any subtle 
variations between the genotypes. 
In conclusion, this research provides evidence for the developmental 
origin of health and disease as it pertains to the immune system. We have shown 
that developmental exposure to the ubiquitous environmental contaminant TCDD 
causes a reprogramming of HSCs such that they are two and a half fold less 
likely to differentiate into mature, committed lymphocytes. We have shown that 
this effect is mediated through the AHR in fetuses, as fetal mice lacking an AHR 
were not affected by the developmental TCDD exposure. Finally, we have 
demonstrated that developmental exposure to TCDD, in crosstalk with Notch1 
overexpressed in a transgenic mouse, alters the progression of a T cell specific 
disease, manifested by development of thymomas. Taken together, they provide 
support for the life-long impact of an early life exposure, and offer a potential 
explanation for the increasing rates of immune disease over the last fifty years. 
This research illustrates the importance of using scientific evidence to drive 
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public health practices such as prenatal supplementation and newborn 
screening, as well as public health policy such as environmental regulations. 
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